EP2829881A2 - Diagnostic for colorectal cancer - Google Patents
Diagnostic for colorectal cancer Download PDFInfo
- Publication number
- EP2829881A2 EP2829881A2 EP20140178981 EP14178981A EP2829881A2 EP 2829881 A2 EP2829881 A2 EP 2829881A2 EP 20140178981 EP20140178981 EP 20140178981 EP 14178981 A EP14178981 A EP 14178981A EP 2829881 A2 EP2829881 A2 EP 2829881A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- m2pk
- igfbp2
- mac2bp
- biomarkers
- epcam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 111
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 107
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 215
- 102000004890 Interleukin-8 Human genes 0.000 claims abstract description 214
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims abstract description 210
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 claims abstract description 208
- 239000000090 biomarker Substances 0.000 claims abstract description 206
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract description 198
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract description 198
- 238000000034 method Methods 0.000 claims abstract description 159
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims abstract description 37
- 101710197901 Galectin-3-binding protein Proteins 0.000 claims abstract description 36
- -1 M2PK Proteins 0.000 claims abstract description 32
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims abstract description 26
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims abstract 9
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims abstract 9
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 161
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 161
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 143
- 230000035945 sensitivity Effects 0.000 claims description 87
- 210000002966 serum Anatomy 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 26
- 210000002381 plasma Anatomy 0.000 claims description 22
- 238000003745 diagnosis Methods 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 102000013009 Pyruvate Kinase Human genes 0.000 claims description 6
- 108020005115 Pyruvate Kinase Proteins 0.000 claims description 6
- 102000001326 Chemokine CCL4 Human genes 0.000 claims description 5
- 108010055165 Chemokine CCL4 Proteins 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 102100030417 Matrilysin Human genes 0.000 claims description 5
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 5
- 108010033760 Amphiregulin Proteins 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 4
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 102000004388 Interleukin-4 Human genes 0.000 claims description 4
- 108090000855 Matrilysin Proteins 0.000 claims description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 4
- 210000001772 blood platelet Anatomy 0.000 claims description 4
- 210000003608 fece Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 3
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 3
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 3
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 102000003814 Interleukin-10 Human genes 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 3
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 3
- 101710108790 Stromelysin-1 Proteins 0.000 claims description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 3
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 3
- 210000003593 megakaryocyte Anatomy 0.000 claims description 2
- 102100038778 Amphiregulin Human genes 0.000 claims 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims 1
- 101150084967 EPCAM gene Proteins 0.000 abstract description 26
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 abstract description 23
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 2
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 199
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 199
- 108091058560 IL8 Proteins 0.000 description 175
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 140
- 239000000523 sample Substances 0.000 description 47
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 34
- 229940096397 interleukin-8 Drugs 0.000 description 34
- 238000012360 testing method Methods 0.000 description 28
- 201000011510 cancer Diseases 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 238000003556 assay Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 238000002790 cross-validation Methods 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 238000002405 diagnostic procedure Methods 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000002052 colonoscopy Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 4
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 4
- 238000000491 multivariate analysis Methods 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000007299 Amphiregulin Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 description 2
- 101000613820 Homo sapiens Osteopontin Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 101150030763 Vegfa gene Proteins 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003384 transverse colon Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZENKESXKWBIZCV-UHFFFAOYSA-N 2,2,4,4-tetrafluoro-1,3-benzodioxin-6-amine Chemical group O1C(F)(F)OC(F)(F)C2=CC(N)=CC=C21 ZENKESXKWBIZCV-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102100036427 Spondin-2 Human genes 0.000 description 1
- 101710092169 Spondin-2 Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 101150111878 Vegfd gene Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009541 flexible sigmoidoscopy Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to determining the presence and/or level of biomarkers for detecting or diagnosing colorectal cancer.
- the invention also relates to diagnostic kits comprising reagents for determining the presence and/or level of the biomarkers and methods of detecting or diagnosing colorectal cancer.
- Colorectal cancer also referred to as colon cancer or bowel cancer
- colon cancer is the second most common cause of cancer worldwide.
- greater than 90% of patients who present while the tumour is still localised will still be alive after 5 years and can be considered cured.
- the early detection of colorectal lesions would therefore significantly reduce the impact of colon cancer (Etzioni et al., 2003).
- FOBT faecal occult blood test
- Flexible sigmoidoscopy a faecal occult blood test
- colonoscopy a faecal occult blood test
- FOBT has relatively low specificity resulting in a high rate of false positives. All positive FOBT must therefore be followed up with colonoscopy. Sampling is done by individuals at home and requires at least two consecutive faecal samples to be analysed to achieve optimal sensitivity. Some versions of the FOBT also require dietary restrictions prior to sampling.
- FOBT also lacks sensitivity for early stage cancerous lesions that do not bleed into the bowel and as stated above, these are the lesions for which treatment is most successful.
- the present inventors investigated over sixty biomarkers associated with colorectal cancer, but found that none of the biomarkers alone would be suitable as a diagnostic test. Surprisingly, it was found that determining the presence and/or level of at least two biomarkers associated with colorectal cancer in a sample from a subject allowed for the detection or diagnosis of colorectal cancer at any of the stages of disease. Determining the presence and/or level of at least two biomarkers advantageously provides a diagnostic test that is at least comparable in sensitivity and specificity to the FOBT.
- the present invention provides a method for diagnosing or detecting colorectal cancer in a subject, the method comprising:
- the method comprises determining the presence and/or level of two biomarkers selected from M2PK, EpCam, IL-13, DKK-3, IL-8 and IGFBP2.
- the method comprises determining the presence and/or level of expression of at least three of the biomarkers.
- the three biomarkers are selected from M2PK, EpCam, IL-13, DKK-3, IL-8, IGFBP2, MIP1 ⁇ , TGF ⁇ 1 and MAC2BP.
- the method comprises determining the presence and/or level of three biomarkers, wherein the three biomarkers are:
- the method comprises determining the presence and/or level of expression of at least four of the biomarkers.
- the method comprises determining the presence and/or level of four biomarkers, wherein the four biomarkers are:
- the method comprises determining the presence and/or level of at least five of the biomarkers.
- the five biomarkers are IL-8, IGFBP2, MAC2BP, M2PK, and IL-13.
- the method comprises determining the presence and/or level of at least six of the biomarkers.
- the method comprises determining the presence and/or level of at least seven of the biomarkers.
- the seven biomarkers are:
- the method comprises determining the presence and/or level of at least eight of the biomarkers.
- the method comprises determining the presence and/or level of at least nine of the biomarkers.
- the method comprises determining the presence and/or level of at least ten of the biomarkers.
- the method comprises determining the presence and/or level of a combination of biomarkers as provided in any of Tables 7 to 18.
- the method comprises detecting the presence and/or level of least one additional biomarker selected from IGF-I, IGF-II, IGF-BP2, Amphiregulin, VEGFA, VEGFD, MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2, ENA-78, MCP-1, MIP-1 ⁇ , IFN- ⁇ , IL-10, IL-13, IL-1 ⁇ , IL-4, IL-8, IL-6, MAC2BP, Tumor M2 pyruvate kinase, M65, OPN, DKK-3, EpCam, TGF ⁇ -1, and VEGFpan.
- additional biomarker selected from IGF-I, IGF-II, IGF-BP2, Amphiregulin, VEGFA, VEGFD, MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2, ENA-78, MCP-1, MIP-1 ⁇ , IFN- ⁇ , IL
- the method diagnoses or detects colorectal cancer with a sensitivity of at least 50%.
- the method diagnoses or detects colorectal cancer with a sensitivity of at least 66%.
- the method diagnoses or detects colorectal cancer with a sensitivity of at least 77%.
- the method diagnoses or detects colorectal cancer with a specificity of at least 75%.
- the method diagnoses or detects colorectal cancer with a specificity of at least 80%.
- the method diagnoses or detects colorectal cancer with a specificity of at least 90%.
- the method diagnoses or detects colorectal cancer with a specificity of at least 95%.
- the method diagnoses or detects Dukes Stage A colorectal cancer with a sensitivity of at least 50% and a specificity of at least 95%.
- the method diagnoses or detects Dukes Stage A colorectal cancer with a sensitivity of at least 60% and a specificity of at least 80%.
- the method diagnoses or detects Dukes Stage A colorectal cancer with a sensitivity of at least 50% and a specificity of at least 90%.
- the method diagnoses or detects TNM Classification T1, N0, M0 or T2, N0, M0 colorectal cancer with a sensitivity of at least 50% and a specificity of at least 95%.
- the method diagnoses or detects TNM Classification T1, N0, M0 or T2, N0, M0 colorectal cancer with a sensitivity of at least 60% and a specificity of at least 80%.
- the method diagnoses or detects TNM Classification T1, N0, M0 or T2, N0, M0 colorectal cancer with a sensitivity of at least 50% and a specificity of at least 90%.
- the method comprises contacting the sample with at least one compound that binds a biomarker polypeptide.
- the method comprises detecting the polypeptides by mass spectrometry.
- the compound is detectably labelled.
- the compound is an antibody.
- the compound is bound to a solid support.
- determining the presence and/or level of the biomarker may comprise determining the presence and/or level of a polynucleotide encoding the biomarker, such as a biomarker gene transcript.
- the biomarkers are polynucleotides.
- the method comprises:
- the sample comprises blood, plasma, serum, urine, platelets, magakaryocytes or faeces.
- the present invention provides a method of treatment comprising:
- the present invention provides a method for monitoring the efficacy of treatment of colorectal cancer in a subject, the method comprising treating the subject for colorectal cancer and then detecting the presence and/or level of at least two biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1 ⁇ , TGF ⁇ 1, and TIMP-1 in a sample from the subject, wherein an absence of and/or reduction in the level of expression of the polypeptides after treatment when compared to before treatment is indicative of effective treatment.
- biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1 ⁇ , TGF ⁇ 1, and TIMP-1
- the present invention provides an array of at least two compounds for the diagnosis or detection of colorectal cancer, wherein each of the compounds binds a different biomarker polypeptide selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1 ⁇ , TGF ⁇ 1, and TIMP-1.
- the present invention provides a kit for diagnosing or detecting colorectal cancer in a subject, the kit comprising two compounds that each binds a different biomarker polypeptide selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1 ⁇ , TGF ⁇ 1, and TIMP-1.
- the recombinant protein, cell culture, and immunological techniques utilized in the present invention are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984 ), J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edn, Cold Spring Harbour Laboratory Press (2001 ), R. Scopes, Protein Purification - Principals and Practice, 3rd edn, Springer (1994 ), T.A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991 ), D.M. Glover and B.D.
- colonal cancer also known as “colon cancer”, “bowel cancer” or “rectal cancer” refers to all forms of cancer originating from the epithelial cells lining the large intestine and/or rectum.
- biomarker refers to any molecule, such as a gene, gene transcript (for example mRNA), peptide or protein or fragment thereof produced by a subject which is useful in differentiating subjects having colorectal cancer from normal or healthy subjects.
- diagnosis and variants thereof such as, but not limited to, “diagnose”, “diagnosed” or “diagnosing” shall not be limited to a primary diagnosis of a clinical state, but should be taken to include diagnosis of recurrent disease.
- the term "subject” refers to any animal that may develop colorectal cancer and includes animals such as mammals, e.g. humans, or non-human mammals such as cats and dogs, laboratory animals such as mice, rats, rabbits or guinea pigs, and livestock animals. In a preferred embodiment, the subject is a human.
- sample may be of any suitable type and may refer, e.g., to a material in which the presence or level of biomarkers can be detected.
- the sample is obtained from the subject so that the detection of the presence and/or level of biomarkers may be performed in vitro. Alternatively, the presence and/or level of biomarkers can be detected in vivo.
- the sample can be used as obtained directly from the source or following at least one step of (partial) purification.
- the sample can be prepared in any convenient medium which does not interfere with the method of the invention.
- the sample is an aqueous solution, biological fluid, cells or tissue.
- the sample is blood, plasma, serum, urine, platelets, megakaryocytes or faeces.
- Pre-treatment may involve, for example, preparing plasma from blood, diluting viscous fluids, and the like.
- Methods of treatment can involve filtration, distillation, separation, concentration, inactivation of interfering components, and the addition of reagents.
- the selection and pre-treatment of biological samples prior to testing is well known in the art and need not be described further.
- treating include administering a therapeutically effective amount of a compound sufficient to reduce or delay the onset or progression of colorectal cancer, or to reduce or eliminate at least one symptom of colorectal cancer.
- the present inventors have shown that determining the presence and/or level of least two biomarkers in a sample from a subject allows for the detection or diagnosis of colorectal cancer, either early detection at Dukes Stage A or at some later stage such as Dukes Stage B or C or D, with specificity and sensitivity comparable to or greater than that achieved with the FOBT.
- the at least two biomarkers that are useful in the methods of the present invention are selected from IL-8 (interleukin-8), IGFBP2 (insulin-like growth factor binding protein-2), MAC2BP (MAC2-binding protein; serum protein 90K), M2PK (pyruvate kinase muscle 2, pyruvate kinase 3), IL-13 (interleukin-13), DKK-3 (dickkopf homolog, 3), EpCAM (epithelial cell adhesion molecule), MIP1 ⁇ (macrophage inflammatory protein 1 ⁇ , CCL4, MIP1beta), TGF ⁇ 1 (transforming growth factor ⁇ 1, TGFbeta1) and TIMP-1 (tissue inhibitor of metalloproteinase 1).
- IL-8 interleukin-8
- IGFBP2 insulin-like growth factor binding protein-2
- MAC2BP MAC2-binding protein
- serum protein 90K serum protein 90K
- M2PK pyruvate kinase muscle 2, pyruvate
- biomarkers includes reference to all polypeptide and polynucleotide variants such as isoforms and transcript variants as would be known by the person skilled in the art. NCBI accession numbers of representative sequences for each of the biomarkers are provided in Table 1. Table 1. NCBI accession numbers for representative biomarker sequences.
- the diagnostic methods of the present invention may involve a degree of quantification to determine levels biomarkers in patient samples. Such quantification is readily provided by the inclusion of appropriate control samples.
- internal controls are included in the methods of the present invention.
- a preferred internal control is one or more samples taken from one or more healthy individuals.
- the term "healthy individual” shall be taken to mean an individual who is known not to suffer from colorectal cancer, such knowledge being derived from clinical data on the individual, including, but not limited to, a different diagnostic assay to that described herein.
- control when internal controls are not included in each assay conducted, the control may be derived from an established data set.
- Data pertaining to the control subjects are preferably selected from the group consisting of:
- the term "typical population” with respect to subjects known to have colorectal cancer shall be taken to refer to a population or sample of subjects diagnosed with colorectal cancer that is representative of the spectrum of colorectal cancer patients. This is not to be taken as requiring a strict normal distribution of morphological or clinicopathological parameters in the population, since some variation in such a distribution is permissible.
- a "typical population” will exhibit a spectrum of colorectal cancer at different stages of disease progression. It is particularly preferred that a "typical population” exhibits the expression characteristics of a cohort of subjects as described herein.
- normal individual shall be taken to mean an individual that does not express a biomarker, or expresses a biomarker at a low level in a sample.
- data obtained from a sufficiently large sample of the population will normalize, allowing the generation of a data set for determining the average level of a particular biomarker.
- Compounds that bind a biomarker when used diagnostically may be linked to a diagnostic reagent such as a detectable label to allow easy detection of binding events in vitro or in vivo.
- a diagnostic reagent such as a detectable label to allow easy detection of binding events in vitro or in vivo.
- Suitable labels include radioisotopes, dye markers or other imaging reagents for detection and/or localisation of target molecules.
- Compounds linked to a detectable label can be used with suitable in vivo imaging technologies such as, for example, radiology, fluoroscopy, nuclear magnetic resonance imaging (MRI), CAT-scanning, positron emission tomography (PET), computerized tomography etc.
- the diagnostic methods of the present invention are able to diagnose or detect colorectal cancer with a sensitivity and specificity that is at least comparable to FOBT, or greater.
- sensitivity refers to the proportion of actual positives in the diagnostic test which are correctly identified as having colorectal cancer.
- Specificity measures the proportion of negatives which are correctly identified as not having colorectal cancer.
- the methods of the invention are able to diagnose or detect colorectal cancer with a sensitivity of at least 50%, 60% or 66%, or at least 77%, 80%, 83%, 85%, 86%, 87%, 88%, 89%, 90%, or at least 93%.
- the methods of the invention are able to diagnose or detect colorectal cancer with a sensitivity of at least 80%, or at least 85% or at least 90%, or at least 95%.
- the methods of the invention are able to diagnose or detect colorectal cancer with a specificity of at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% or at least 95%.
- the methods of the present invention are able to detect colorectal cancer at all of the Dukes Stages with greater sensitivity than the FOBT.
- the tumor has penetrated into, but not through, the bowel wall.
- the tumor has penetrated through the bowel wall but there is not yet any lymph node involvement.
- the cancer involves regional lymph nodes.
- there is distant metastasis for example, to the liver or lung.
- the methods of the present invention are able to diagnose or detect colorectal cancer at any Dukes Stage with a sensitivity of at least 80%.
- TMM Malignant Tumors
- AJCC American Joint Committee on Cancer
- MAC Modified Astler-Coller classification
- the Dukes Stages correspond to certain TNM Classifications.
- Dukes Stage A corresponds to T1, T2, N0 and M0
- Dukes Stage B corresponds to T3, T4a, T4b, N0 and M0
- Dukes Stage C corresponds to i) T1-T2, N1/N1c, M0; ii) T1, N2a and M0; iii) T3-T4a, N1/N1c and M0; iv) T2-T3, N2a and M0; v) T1-T2, N2b and M0; vi) T4a, N2a and M0; vii) T3-T4a, N2b and M0; and viii) T4b, N1-N2 and M0.
- reference to a Dukes Stage as used herein includes reference to the corresponding TMN classification as known in the art.
- biomarker polypeptide is detected in a patient sample, wherein the presence and/or level of the polypeptide in the sample is indicative of colorectal cancer.
- the method may comprise contacting a biological sample derived from the subject with a compound capable of binding to a biomarker polypeptide, and detecting the formation of complex between the compound and the biomarker polypeptide.
- biomarker polypeptide as used herein includes fragments of biomarker polypeptides, including for example, immunogenic fragments and epitopes of the biomarker polypeptide.
- the compound that binds the biomarker is an antibody.
- antibody as used herein includes intact molecules as well as molecules comprising or consisting of fragments thereof, such as, for example Fab, F(ab')2, Fv and scFv, as well as engineered variants including diabodies, triabodies, mini-bodies and single-domain antibodies which are capable of binding an epitopic determinant.
- antibodies may exist as intact immunoglobulins, or as modifications in a variety of forms.
- an antibody to a biomarker polypeptide is detected in a patient sample, wherein the presence and/or level of the antibody in the sample is indicative of colorectal cancer.
- Preferred detection systems contemplated herein include any known assay for detecting proteins or antibodies in a biological sample isolated from a human subject, such as, for example, SDS/PAGE, isoelectric focussing, 2-dimensional gel electrophoresis comprising SDS/PAGE and isoelectric focussing, an immunoassay, flow cytometry e.g. fluorescence-activated cell sorting (FACS), a detection based system using an antibody or non-antibody compound, such as, for example, a small molecule (e.g. a chemical compound, agonist, antagonist, allosteric modulator, competitive inhibitor, or non-competitive inhibitor, of the protein).
- FACS fluorescence-activated cell sorting
- the antibody or small molecule may be used in any standard solid phase or solution phase assay format amenable to the detection of proteins.
- Optical or fluorescent detection such as, for example, using mass spectrometry, MALDI-TOF, biosensor technology, evanescent fiber optics, or fluorescence resonance energy transfer, is clearly encompassed by the present invention.
- Assay systems suitable for use in high throughput screening of mass samples e.g. a high throughput spectroscopy resonance method (e.g. MALDI-TOF, electrospray MS or nano-electrospray MS), are also contemplated.
- Another suitable protein detection technique involves the use of Multiple Reaction Monitoring (MRM) in LC-MS (LC/MRM-MS) (Anderson and Hunter, 2006).
- MRM Multiple Reaction Monitoring
- Immunoassay formats are particularly suitable, e.g., selected from the group consisting of, an immunoblot, a Western blot, a dot blot, an enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), enzyme immunoassay.
- Modified immunoassays utilizing fluorescence resonance energy transfer (FRET), isotope-coded affinity tags (ICAT), matrix-assisted laser desorption/ionization time of flight (MALDI-TOF), electrospray ionization (ESI), biosensor technology, evanescent fiber-optics technology or protein chip technology are also useful.
- nucleic acid molecule or “polynucleotide” as used herein refer to an oligonucleotide, polynucleotide or any fragment thereof.
- Comparison may be made by reference to a standard control, or to a control level that is found in healthy tissue.
- levels of a transcribed gene can be determined by Northern blotting, and/or RT-PCR.
- quantitative (real-time) PCR quantitative analysis of gene expression can be achieved by using appropriate primers for the gene of interest.
- the nucleic acid may be labelled and hybridised on a gene array, in which case the gene concentration will be directly proportional to the intensity of the radioactive or fluorescent signal generated in the array.
- PCR methods that may be used in carrying out the invention include hybridization based PCR detection systems, TaqMan assay ( US 5,962,233 ) and the molecular beacon assay ( US 5,925,517 ).
- RNA may be isolated from a sample to be analysed using conventional procedures, such as are supplied by QIAGEN technology. This RNA is then reverse-transcribed into DNA using reverse transcriptase and the DNA molecule of interest may then be amplified by PCR techniques using specific primers.
- Hybridisation or amplification assays such as, for example, Southern or Northern blot analysis, immunohistochemistry, single-stranded conformational polymorphism analysis (SSCP) and PCR analyses are among techniques that are useful in this respect.
- target or probe nucleic acid may be immobilised to a solid support such as a microtitre plate, membrane, polystyrene bead, glass slide or other solid phase.
- kits for the diagnosis or detection of colorectal cancer may be suitable for detection of nucleic acid species, or alternatively may be for detection of a polypeptide gene product, as discussed above.
- kits For detection of polypeptides, antibodies will most typically be used as components of kits. However, any agent capable of binding specifically to a biomarker gene product will be useful in this aspect of the invention.
- Other components of the kits will typically include labels, secondary antibodies, substrates (if the gene is an enzyme), inhibitors, co-factors and control gene product preparations to allow the user to quantitate expression levels and/or to assess whether the diagnosis experiment has worked correctly. Enzyme-linked immunosorbent assay-based (ELISA) tests and competitive ELISA tests are particularly suitable assays that can be carried out easily by the skilled person using kit components.
- the kit further comprises means for the detection of the binding of an antibody to a biomarker polypeptide.
- a reporter molecule such as, for example, an enzyme (such as horseradish peroxidase or alkaline phosphatase), a dye, a radionucleotide, a luminescent group, a fluorescent group, biotin or a colloidal particle, such as colloidal gold or selenium.
- an enzyme such as horseradish peroxidase or alkaline phosphatase
- a dye such as horseradish peroxidase or alkaline phosphatase
- a radionucleotide such as a radionucleotide
- a luminescent group such as a fluorescent group
- biotin or a colloidal particle such as colloidal gold or selenium.
- a colloidal particle such as colloidal gold or selenium.
- a kit may additionally comprise a reference sample.
- a reference sample comprises a polypeptide that is detected by an antibody.
- the polypeptide is of known concentration.
- Such a polypeptide is of particular use as a standard. Accordingly, various known concentrations of such a polypeptide may be detected using a diagnostic assay described herein.
- kits may contain a first container such as a vial or plastic tube or a microtiter plate that contains an oligonucleotide probe.
- the kits may optionally contain a second container that holds primers.
- the probe may be hybridisable to DNA whose altered expression is associated with colorectal cancer and the primers are useful for amplifying this DNA.
- Kits that contain an oligonucleotide probe immobilised on a solid support could also be developed, for example, using arrays (see supplement of issue 21(1) Nature Genetics, 1999 ).
- nucleic acid primers may be included in the kit that are complementary to at least a portion of a biomarker gene as described herein.
- the set of primers typically includes at least two oligonucleotides, preferably four oligonucleotides, that are capable of specific amplification of DNA.
- Fluorescent-labelled oligonucleotides that will allow quantitative PCR determination may be included (e.g. TaqMan chemistry, Molecular Beacons). Suitable enzymes for amplification of the DNA, will also be included.
- Control nucleic acid may be included for purposes of comparison or validation. Such controls could either be RNA/DNA isolated from healthy tissue, or from healthy individuals, or housekeeping genes such as ⁇ -actin or GAPDH whose mRNA levels are not affected by colorectal cancer.
- test performance In order to develop a panel of biomarkers suitable for diagnosing or detecting colorectal cancer, the present inventors have analysed numerous biomarkers in a statistical model. Such an improvement in the performance of a test is sometimes referred to as the "in-sample" performance.
- a fair evaluation of a test requires its assessment using out-of-sample subjects, that is, subjects not included in the construction of the initial predictive model. This is achieved by assessing the test performance using cross validation.
- Tests for stastical significance include linear and non linear regression, including ANOVA, Kruskal-Wallis, Wilcoxon, Mann-Whitney and odds ratio, Baysian probability algorithms. As the number of biomarkers measured increases however, it can be generally more convenient to use a more sophisticated technique such as Random Forests, simple logistic, Bayes Net to name a few.
- Bayesian probability may be adopted.
- a 10-fold cross-validation can be used to estimate the "out-of-sample” performance of the models in question.
- the data can be divided randomly into 10 sub-samples, each with similar proportions of healthy subject and subjects at each stage of disease.
- each subsample can be excluded, and a logistic model built using the remaining 90% of the subjects.
- This model can then be used to estimate the probability of cancer for the excluded sub-sample, providing an estimate of "out-of-sample” performance.
- "out-of-sample” performance can be estimated from the study data itself.
- These out-of sample predicted probabilities can then be compared with the actual disease status of the subjects to create a Receiver Operating Characteristic (ROC) Curve, from which the cross-validated sensitivity at 95% specificity may be estimated.
- ROC Receiver Operating Characteristic
- Each C i is the logarithm of concentration biomarker i in the plasma (or serum) of a person.
- Each beta ( ⁇ ) is a coefficient applying to that biomarker in the concentration units in which it is measured - ⁇ 0 is an "offset" or "intercept".
- the present invention also provides software or hardware programmed to implement an algorithm that processes data obtained by performing the method of the invention via a multivariate analysis to provide a disease score and provide or permit a diagnosis or detection of colorectal cancer and/or determine progression or status of a colorectal cancer or determine whether or not a colorectal cancer has progressed or determine whether or not a subject is responding to treatment for colorectal cancer in accordance with the results of the disease score in comparison with predetermined values.
- a method of the invention may be used in existing knowledge-based architecture or platforms associated with pathology services. For example, results from a method described herein are transmitted via a communications network (e.g. the internet) to a processing system in which an algorithm is stored and used to generate a predicted posterior probability value which translates to the score of disease probability or risk of recurrence or metastasis or responsiveness to treatment which is then forwarded to an end user in the form of a diagnostic or predictive report.
- a communications network e.g. the internet
- the method of the invention may, therefore, be in the form of a kit or computer-based system which comprises the reagents necessary to detect the concentration of the biomarkers and the computer hardware and/or software to facilitate determination and transmission of reports to a clinician.
- the assay of the present invention permits integration into existing or newly developed pathology architecture or platform systems.
- the present invention contemplates a method of allowing a user to determine the status of a subject with respect to colorectal cancer, the method including:
- the method for diagnosing or detecting colorectal cancer of the invention may be performed by taking a blood sample from a patient and determining the presence and/or level of any one or more of the biomarkers as described herein. If desired, the measurements may be made, for example, on a biochip so that a single analysis can be used to measure the presence and/or level of multiple biomarkers. The results of this analysis may then be inputted into into a computer program that subjects them to linear regression analysis. The computer could also contain information as to control values or expected ranges, or the clinician, nurse, medcal administrator or general practitioner could input such data. This analysis wold then provide a score or likelihood of having colorectal cancer. If a second test for the patient is performed, the regression analysis may indicate a change in the score, thus indicating that the patient's disease has progressed or worsened.
- a collection of plasma and serum samples was taken and processed from a cohort of colorectal cancer patients (Dukes Stages A-D) that were being treated at several hospitals.
- Blood was also collected and processed from a group of about 50 healthy volunteers over the age of 65 and from a group of 15 over the age of 50.
- Study 1 looked at 52 cancer samples and 50 controls
- study 2 looked at 55 cancer samples and 53 controls
- study 3 and 4 looked at 96 cancer samples and 50 controls.
- study 2 looked at 55 cancer samples and 53 controls
- study 3 and 4 looked at 96 cancer samples and 50 controls.
- study 2 3 and 4 the patients were age and gender matched across Dukes Stages, see Table 2 for summary statistics.
- Table 2 Characteristics of normal volunteers and colorectal cancer patients used in studies 2, 3 and 4.
- Biomarkers chosen to be measured in Study 1 and 2 and 3 are listed in Table 3. Biomarkers in bold were those identified as promising from each study (i.e. they were significantly different in samples from colorectal cancer patients versus control and/or they were identified in panels of combined biomarkers that distinguish colorectal cancer from controls). Table 3. Biomarkers analysed in studies.
- the resulting model was then used to estimate the probability that the excluded observation is a case. This was repeated for each observation in the dataset. In this way each observation in turn acted as an independent test of the model-building algorithm.
- the resulting dataset consisting of cases and controls each with an "independently predicted" case probability can then be compared with the original model.
- the ability to choose from numerous biomarkers and weight them appropriately allows a search strategy which optimises performance in regions of interest on the ROC curve.
- the cost of poor specificity is large numbers of unnecessary colonoscopies.
- biomarkers were evaluated to select a candidate panel of colorectal cancer biomarkers, using block randomization within plates to avoid bias. From this list of 48 only 42 showed measurable levels. Individually 14 biomarkers showed significant difference between controls and CRC as assessed by t-tests; (IGFII, IGFBP2, IL-8, IL-6, MMP-1, MMP-7, s90/Mac2BP, M2PK, EpCam, TIMP-1 (serum and plasma), M65, OPN, TGF ⁇ 1, VEGFpan. As expected, none had sufficient sensitivity or specificity to be useful as a biomarker by itself (not shown). However, using a variety of modelling strategies, including use of logarithmic values, several different panels of biomarkers were found that exceeded the performance of FOBT especially for early to late stage disease.
- Figure 1 shows the results from a 7 biomarker panel which included IL8 (serum), IL-13 (serum), EpCAM (plasma), M2PK (plasma), IGFBP2 (serum) and Mac2BP (serum) and which was cross validated to predict its performance on independent samples.
- Biomarker Measured in Concentration Units Coefficient Intercept NA NA -37.74 IL-8 serum pg/mL 1.07 IL-13 serum pg/mL -0.28 EpCAM plasma pg/mL -0.33 M2PK plasma units/mL 1.40 IGFBP2 serum ng/mL 1.99 Mac2BP serum ng/mL 2.39 MIP1beta Serum Pg/ml -1.19 Table 5. Performance of the 7 biomarker model and cross-validation. Model estimate Cross validation Area Under the ROC Curve (AUC) 0.91 0.86 Sensitivity at 80% specificity 0.84 0.78 Sensitivity at 90% specificity 0.81 0.69
- biomarkers were remeasured in the same cohort as Study 3. Blood was collected from 96 colorectal cancer patients and 50 normal subjects (the controls). In this study the focus was on 10 biomarkers, namely IGFBP2, IL8, IL13,Mac2BP, M2PK, Dkk3, EpCam, TGFbeta1, TIMP-1, MIP1beta. Assays were performed as described previously. Both serum and plasma levels of each of the biomarkers were measured and compared with control values.
- Biomarker 1 Biomarker 2 Estimated In-Sample (Test) Sensitivity at 95% Specificity Estimated Out-of-Sample (Cross-Validated) Sensitivity at 95% Specificity M2PK EpCAM 58.3% 58.3% M2PK IL13 56.3% 57.3% Dkk3 M2PK 55.2% 55.2% M2PK IL8 60.4% 54.2% M2PK IGFBP2 58.3% 52.1%
- the 968 combinations of between 3 and 10 biomarkers consist of the 120 combinations of 3 marker; 210 combinations of 4 markers; 252 combinations of 5 markers; 210 combinations of 6 markers; 120 combinations of 7 markers; 45 combinations of 8 markers; 10 combinations of 9 markers and the single combination that includes all 10 biomarkers.
- the 968 combinations had a sensitivity of 50% at a specificity of 95%, see Figure 4 which shows the results for a three biomarker combination. More than half of these combinations would have a specificity of 90% and a sensitivity of 50%.
- Figure 5 shows all 485 of the estimated out-of sample (10-fold cross-validated) ROC curves for tests out of a total possible 968 models based on all possible combinations of 3 to 10 of the biomarkers. Note that many individual segments of the 485 ROC curves are coincident, due to as each horizontal segment represents one control and each vertical segment one case. In this instance 50.1% of the combinations have exceeded the 50% sensitivity, 95% specificity, The best estimated "out-of sample” performance is a sensitivity of 76% at 95% specificity. Repeating the cross-validation will select a different set of models - the sensitivity of any one combination may vary by 10% at 95% specificity due to random sampling - but result in a similar proportion of useful "useful screening tests". Precise validation of individual models requires repeated experiments and larger sample sizes.
- Figure 6 shows how many of the 485 combinations with 50% sensitivity, 95% specificity, include any given biomarker.
- 432 of the chosen “useful” combinations include M2PK.
- MIP1beta At the low end 227 of the chosen “useful” combinations include MIP1beta.
- Figures 7 to Figure 11 demonstrate some of the results from this last study (Study 4) for combinations of 5 and 7 biomarkers, including a model where the samples are either from plasma or serum cluster.
- Figure 11 demonstrates the validity of the choice of three biomarkers (DKK-3, M2PK and IGFBP2) at different stages of the disease progression. The data indicates that at Stage A if the three markers are used, the test still will achieve a signifcant senstivity (64%) at 95 % specificity which is comparable to the sensitivity achieved at late stage disease, 79%). That is the biomarker panel of three will pick up early disease states allowing early detection.
- Tables 8 to 16 list results from various combinations of various biomarker panel sets. Depending on the linear regression that is used, as well as the cohort control and other factors such as sample derivation and assay kit technique, there may be a variation on the actual figures or order of the markers. Regardless, many of these combinations will achieve good selectivity at high specificities so as to be useful for diagnosing or detecting colorectal cancer at any stage of the disease progression. Table 8. Combination of three biomarkers in serum that equal or exceed 50% sensitivity at 95% specificity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- The present invention relates to determining the presence and/or level of biomarkers for detecting or diagnosing colorectal cancer. The invention also relates to diagnostic kits comprising reagents for determining the presence and/or level of the biomarkers and methods of detecting or diagnosing colorectal cancer.
- Colorectal cancer, also referred to as colon cancer or bowel cancer, is the second most common cause of cancer worldwide. There is an annual incidence of almost a million colorectal cancer cases with an annual mortality around 500,000 (Cancer in Australia: an overview, 2008). Unfortunately, 30-50% of patients have occult or overt metastases at presentation and once tumours have metastasized prognosis is very poor with a five year survival of less than 10% (Etzioni et al., 2003). By contrast, greater than 90% of patients who present while the tumour is still localised will still be alive after 5 years and can be considered cured. The early detection of colorectal lesions would therefore significantly reduce the impact of colon cancer (Etzioni et al., 2003).
- The current screening assays in widespread use for the diagnosis of colorectal cancer are the faecal occult blood test (FOBT), flexible sigmoidoscopy, and colonoscopy (Lieberman, 2010). FOBT has relatively low specificity resulting in a high rate of false positives. All positive FOBT must therefore be followed up with colonoscopy. Sampling is done by individuals at home and requires at least two consecutive faecal samples to be analysed to achieve optimal sensitivity. Some versions of the FOBT also require dietary restrictions prior to sampling. FOBT also lacks sensitivity for early stage cancerous lesions that do not bleed into the bowel and as stated above, these are the lesions for which treatment is most successful.
- While FOBT screening does result in reduction of mortality due to colorectal cancer it suffers from a low compliance rate (30-40%), most likely due to the unpalatable nature of the test, which limits its usefulness as a screening tool. Colonoscopy is the current gold standard and has a specificity of greater then 90% but it is intrusive and costly with a small but finite risk of complications (2.1 per 1000 procedures) (Levin, 2004). Development of a rapid, specific, cheap blood based assay would overcome compliance issues commonly seen with other screening tests (Tonus, 2006; Hundt et al., 2007) and would be more acceptable as part of a large screening assay.
- The present inventors investigated over sixty biomarkers associated with colorectal cancer, but found that none of the biomarkers alone would be suitable as a diagnostic test. Surprisingly, it was found that determining the presence and/or level of at least two biomarkers associated with colorectal cancer in a sample from a subject allowed for the detection or diagnosis of colorectal cancer at any of the stages of disease. Determining the presence and/or level of at least two biomarkers advantageously provides a diagnostic test that is at least comparable in sensitivity and specificity to the FOBT.
- Accordingly, in one aspect, the present invention provides a method for diagnosing or detecting colorectal cancer in a subject, the method comprising:
- i) determining the presence and/or level of at least two biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1 in a sample from the subject,
wherein the presence and/or level of the two biomarkers is indicative of colorectal cancer. - In one embodiment, the method comprises determining the presence and/or level of two biomarkers selected from M2PK, EpCam, IL-13, DKK-3, IL-8 and IGFBP2.
- In another embodiment, the method comprises determining the presence and/or level of expression of at least three of the biomarkers.
- In one embodiment, the three biomarkers are selected from M2PK, EpCam, IL-13, DKK-3, IL-8, IGFBP2, MIP1β, TGFβ1 and MAC2BP.
- In one particular embodiment, the method comprises determining the presence and/or level of three biomarkers, wherein the three biomarkers are:
- i) DKK-3, M2PK, and IGFBP2;
- ii) M2PK, IGFBP2, and EpCAM;
- iii) M2PK, MIP1β, and TGFβ1; or
- iv) IL-8, IL-13, and MAC2BP.
- In another embodiment, the method comprises determining the presence and/or level of expression of at least four of the biomarkers.
- In one particular embodiment, the method comprises determining the presence and/or level of four biomarkers, wherein the four biomarkers are:
- i) DKK-3, M2PK, MAC2BP, and IGFBP2;
- ii) IL-8, IL-13, MAC2BP, and EpCam;
- iii) DKK3, M2PK, TGFβ1, and TIMP-1;
- iv) M2PK, MIP1β, IL-13, and TIMP-1; or
- v) IL-8, MAC2BP, IGFBP2, and EpCam.
- In yet another embodiment, the method comprises determining the presence and/or level of at least five of the biomarkers.
- In one particular embodiment, the five biomarkers are IL-8, IGFBP2, MAC2BP, M2PK, and IL-13.
- In another embodiment, the method comprises determining the presence and/or level of at least six of the biomarkers.
- In another embodiment, the method comprises determining the presence and/or level of at least seven of the biomarkers.
- In one particular embodiment, the seven biomarkers are:
- i) IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, and TGF β1; or
- ii) IL-8, IGFBP2, MAC2BP, M2PK, IL-13, EpCam, and MIP1β.
- In yet another embodiment, the method comprises determining the presence and/or level of at least eight of the biomarkers.
- In one embodiment, the method comprises determining the presence and/or level of at least nine of the biomarkers.
- In yet another embodiment, the method comprises determining the presence and/or level of at least ten of the biomarkers.
- In another embodiment, the method comprises determining the presence and/or level of a combination of biomarkers as provided in any of Tables 7 to 18.
- In another embodiment, the method comprises detecting the presence and/or level of least one additional biomarker selected from IGF-I, IGF-II, IGF-BP2, Amphiregulin, VEGFA, VEGFD, MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2, ENA-78, MCP-1, MIP-1β, IFN-γ, IL-10, IL-13, IL-1β, IL-4, IL-8, IL-6, MAC2BP, Tumor M2 pyruvate kinase, M65, OPN, DKK-3, EpCam, TGFβ-1, and VEGFpan.
- In one embodiment, the method diagnoses or detects colorectal cancer with a sensitivity of at least 50%.
- In another embodiment, the method diagnoses or detects colorectal cancer with a sensitivity of at least 66%.
- In yet another embodiment, the method diagnoses or detects colorectal cancer with a sensitivity of at least 77%.
- In one embodiment, the method diagnoses or detects colorectal cancer with a specificity of at least 75%.
- In one embodiment, the method diagnoses or detects colorectal cancer with a specificity of at least 80%.
- In another embodiment, the method diagnoses or detects colorectal cancer with a specificity of at least 90%.
- In yet another embodiment, the method diagnoses or detects colorectal cancer with a specificity of at least 95%.
- In another embodiment, the method diagnoses or detects Dukes Stage A colorectal cancer with a sensitivity of at least 50% and a specificity of at least 95%.
- In yet another embodiment, the method diagnoses or detects Dukes Stage A colorectal cancer with a sensitivity of at least 60% and a specificity of at least 80%.
- In another embodiment, the method diagnoses or detects Dukes Stage A colorectal cancer with a sensitivity of at least 50% and a specificity of at least 90%.
- The skilled person will understand that Dukes Stage A corresponds to TNM Classifications T1, N0, M0 and T2, N0, M0.
- Thus in one embodiment, the method diagnoses or detects TNM Classification T1, N0, M0 or T2, N0, M0 colorectal cancer with a sensitivity of at least 50% and a specificity of at least 95%.
- In yet another embodiment, the method diagnoses or detects TNM Classification T1, N0, M0 or T2, N0, M0 colorectal cancer with a sensitivity of at least 60% and a specificity of at least 80%.
- In another embodiment, the method diagnoses or detects TNM Classification T1, N0, M0 or T2, N0, M0 colorectal cancer with a sensitivity of at least 50% and a specificity of at least 90%.
- Any suitable technique for the detection of polypeptides may be used in the methods of the invention. In one embodiment, the method comprises contacting the sample with at least one compound that binds a biomarker polypeptide. Alternatively, the method comprises detecting the polypeptides by mass spectrometry.
- In one particular embodiment, the compound is detectably labelled.
- In another embodiment, the compound is an antibody.
- In one embodiment, the compound is bound to a solid support.
- In the methods of the invention, determining the presence and/or level of the biomarker may comprise determining the presence and/or level of a polynucleotide encoding the biomarker, such as a biomarker gene transcript. Thus, in one embodiment, the biomarkers are polynucleotides.
- In yet another embodiment of the methods of the invention, the method comprises:
- i) determining the presence and/or level of the biomarkers in the sample from the subject; and
- ii) comparing the presence and/or level of the biomarkers to a control, wherein a presence and/or level in the sample that is different to the control is indicative of colorectal cancer.
- In one embodiment, the sample comprises blood, plasma, serum, urine, platelets, magakaryocytes or faeces.
- In another aspect, the present invention provides a method of treatment comprising:
- (i) diagnosing or detecting colorectal cancer according to the method of the invention; and
- (ii) administering or recommending a therapeutic for the treatment of colorectal cancer.
- In yet another aspect, the present invention provides a method for monitoring the efficacy of treatment of colorectal cancer in a subject, the method comprising treating the subject for colorectal cancer and then detecting the presence and/or level of at least two biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1 in a sample from the subject, wherein an absence of and/or reduction in the level of expression of the polypeptides after treatment when compared to before treatment is indicative of effective treatment.
- In another aspect, the present invention provides an array of at least two compounds for the diagnosis or detection of colorectal cancer, wherein each of the compounds binds a different biomarker polypeptide selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1.
- In yet another aspect, the present invention provides a kit for diagnosing or detecting colorectal cancer in a subject, the kit comprising two compounds that each binds a different biomarker polypeptide selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1.
- Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
- As will be apparent, preferred features and characteristics of one aspect of the invention are applicable to many other aspects of the invention.
- The invention is hereinafter described by way of the following non-limiting Examples and with reference to the accompanying figures.
-
-
Figure 1 . InStudy 3 an optimum combination of the 46 potential protein biomarkers was found using logistic regression modelling, resulting in a panel of seven biomarkers and is illustrated as a ROC curve (black curve). The performance of this "panel" on independent data was estimated using "leave one out" cross-validation (grey curve). The vertical lines are drawn at points of 80% and 90% specificity - operating points of interest in screening tests. Performance statistics are given in Table 5. -
Figure 2 . Performance of a seven biomarker model identifying colorectal cancer patients from normals at each Dukes Stage illustrated by ROC curves for each stage. A (red)- Stage A, B (green)- Stage B, C (blue)- Stage C, and D (black)-Stage D from Study 3a. Performance characteristics are given in Table 6. -
Figure 3 . When biomarker results from Study 4 (also referred to asStudy 3 remeasured) were modelled in pairs a total of 5 pairs (out of a possible 45 combinations selected from the list of 10 biomarkers above) could be shown to produce a sensitivity above 52% at a specificity of 95. The performance of these pair wise biomarker combinations is illustrated as ROC curves (n =5 curves). Performance characteristics are given in Table 7. -
Figure 4 . An example of a 3 biomarker model generated from Study 4 data which had a sensitivity of at least 50% at 95% specificity. There were 968 possible 3 - 10 biomarker combinations and approximately half of those combinations showed a performance of at least 50% sensitivity at 90% specificity. -
Figure 5 . ROC curves are illustrated for all combinations of 3-10 biomarkers generated from Study 4 data which have a sensitivity of at least 50% at 95% specificity (n = 485 cross validated curves out of a possible 968 models). -
Figure 6 . Frequency of each biomarker in the best 485 models. These BMs represent all serum models that gave a sensitivity of at least 50% at 95% The high representation of all 10 biomarkers in the useful models demonstrates the unity of our selection of these 10 biomarkers. -
Figure 7 . A 5 biomarker model generated from Study 4 data is illustrated as a ROC curve (black) and cross validated ROC curve (grey). This model shows a sensitivity of 68% at 95% specificity when all stages of disease are included and when cross validated gave a sensitivity of 64%. Biomarkers included are [IL-8, IGFBP2, Mac2BP, DKK-3 and M2PK]. -
Figure 8 . A 6 biomarker model generated from Study 4 data is illustrated as a ROC curve (black) and cross validated ROC curve (Grey). This model shows a senstivity of 77% at a specificity of 95% when all stages of disease are included and when cross validated gave a sensitivity of 67%. Biomarkers included are [IL-8, IGFBP2, Mac2BP, DKK-3, TGFbeta1&M2PK]. -
Figure 9 . Two alternative seven biomarker models generated from Study 3a data are shown. One was optimised for high specificity (black/new) and an alternative or model optimised for area under the curve is shown (grey/old). At 90% specificity the sensitivity was 72% for the new model and 77% for the older model. Biomarkers included were as follows:- New : IL8,IGFBP2, s90MAC2BP, M2PK, DKK-3, IL-13 & TGFbeta,
- Old : IL8, IGFBP2, s90MAC2BP, M2PK, EpCAM, IL13 & MIP-1b.
-
Figure 10 . A seven biomarker model generated from Study 4 data is illustrated as a ROC curve (black) and cross validated ROC curve (grey). This model shows , a sensitivity of 84% at a specificity of 95%. Biomarkers included are [M2PK serum, IL8.plasma, TGF betal.serum, IGFBP2.plasma,Mac2BP.serum, TIMP1.plasma and Dkk3 plasma. -
Figure 11 . Cross validated ROC curves showing the performance of a 3 biomarker model for each Dukes stage is illustrated. This data demonstrates the validity of the choice of three biomarkers (DKK-3, M2PK and IGFBP2) for detecting cancer at different stages of the disease progression. The data indicates that at Stage A if the three markers are used, the test still will achieve a significant sensitivity of 64% at 95 % specificity which is comparable to the sensitivity achieved at late stage disease (79%). That is the biomarker panel of three will pick up early disease states allowing early detection. Biomarkers included are Dkk3, M2PK and IGFBP2. -
- SEQ ID NO:1 - amino acid sequence of IL-8
- SEQ ID NO:2 - amino acid sequence of IGFBP2
- SEQ ID NO:3 - amino acid sequence of MAC2BP
- SEQ ID NO:4 - amino acid sequence of
M2PK variant 1 - SEQ ID NO:5 - amino acid sequence of M2PK variant 2
- SEQ ID NO:6 - amino acid sequence of
M2PK variant 3 - SEQ ID NO:7 - amino acid sequence of IL-13
- SEQ ID N0:8 - amino acid sequence of DKK-3
variant 1 - SEQ ID NO:9 - amino acid sequence of DKK-3 variant 2
- SEQ ID NO:10 - amino acid sequence of DKK-3
variant 3 - SEQ ID NO:11- amino acid sequence of EpCam
- SEQ ID NO:12- amino acid sequence of MIP1β
- SEQ ID NO:13- amino acid sequence of TGFβ1
- SEQ ID NO:14 - amino acid sequence of TIMP-1
- Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, immunology, immunohistochemistry, protein chemistry, and biochemistry).
- Unless otherwise indicated, the recombinant protein, cell culture, and immunological techniques utilized in the present invention are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edn, Cold Spring Harbour Laboratory Press (2001), R. Scopes, Protein Purification - Principals and Practice, 3rd edn, Springer (1994), T.A. Brown (editor), Essential Molecular Biology: A Practical Approach, ), D.M. Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F.M. Ausubel et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present), Ed Harlow and David Lane (editors) Antibodies: A Laboratory Manual, Cold Spring Harbour Laboratory, (1988), and J.E. Coligan et al. (editors) Current Protocols in Immunology, John Wiley & Sons (including all updates until present).
- As used herein, the term "colorectal cancer", also known as "colon cancer", "bowel cancer" or "rectal cancer", refers to all forms of cancer originating from the epithelial cells lining the large intestine and/or rectum.
- As used herein, "biomarker" refers to any molecule, such as a gene, gene transcript (for example mRNA), peptide or protein or fragment thereof produced by a subject which is useful in differentiating subjects having colorectal cancer from normal or healthy subjects.
- As used herein, the term "diagnosis", and variants thereof such as, but not limited to, "diagnose", "diagnosed" or "diagnosing" shall not be limited to a primary diagnosis of a clinical state, but should be taken to include diagnosis of recurrent disease.
- As used herein, the term "subject" refers to any animal that may develop colorectal cancer and includes animals such as mammals, e.g. humans, or non-human mammals such as cats and dogs, laboratory animals such as mice, rats, rabbits or guinea pigs, and livestock animals. In a preferred embodiment, the subject is a human.
- The "sample" may be of any suitable type and may refer, e.g., to a material in which the presence or level of biomarkers can be detected. Preferably, the sample is obtained from the subject so that the detection of the presence and/or level of biomarkers may be performed in vitro. Alternatively, the presence and/or level of biomarkers can be detected in vivo. The sample can be used as obtained directly from the source or following at least one step of (partial) purification. The sample can be prepared in any convenient medium which does not interfere with the method of the invention. Typically, the sample is an aqueous solution, biological fluid, cells or tissue. Preferably, the sample is blood, plasma, serum, urine, platelets, megakaryocytes or faeces. Pre-treatment may involve, for example, preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, separation, concentration, inactivation of interfering components, and the addition of reagents. The selection and pre-treatment of biological samples prior to testing is well known in the art and need not be described further.
- As used herein the terms "treating", "treat" or "treatment" include administering a therapeutically effective amount of a compound sufficient to reduce or delay the onset or progression of colorectal cancer, or to reduce or eliminate at least one symptom of colorectal cancer.
- The present inventors have shown that determining the presence and/or level of least two biomarkers in a sample from a subject allows for the detection or diagnosis of colorectal cancer, either early detection at Dukes Stage A or at some later stage such as Dukes Stage B or C or D, with specificity and sensitivity comparable to or greater than that achieved with the FOBT. The at least two biomarkers that are useful in the methods of the present invention are selected from IL-8 (interleukin-8), IGFBP2 (insulin-like growth factor binding protein-2), MAC2BP (MAC2-binding protein; serum protein 90K), M2PK (pyruvate kinase muscle 2, pyruvate kinase 3), IL-13 (interleukin-13), DKK-3 (dickkopf homolog, 3), EpCAM (epithelial cell adhesion molecule), MIP1β (macrophage inflammatory protein 1β, CCL4, MIP1beta), TGFβ1 (transforming growth factor β1, TGFbeta1) and TIMP-1 (tissue inhibitor of metalloproteinase 1). Reference to any of these biomarkers includes reference to all polypeptide and polynucleotide variants such as isoforms and transcript variants as would be known by the person skilled in the art. NCBI accession numbers of representative sequences for each of the biomarkers are provided in Table 1.
Table 1. NCBI accession numbers for representative biomarker sequences. Biomarker Representative NCBI Accession Numbers IL-8 NM_000584.2 (SEQ ID NO:1) IGFBP2 NM_000597.2 (SEQ ID NO:2) MAC2BP NM_005567.3 (SEQ ID NO:3) M2PK NM_002654.3; NM_182470.1; NM_182471.1 (SEQ ID NOs:4-6) IL-13 NM_002188.2 (SEQ ID NO:7) DKK-3 NM_015881.5; NM_013253; NM-001018057.1 (SEQ ID NOs:8-10) EpCam NM_002354.2 (SEQ ID NO:11) MIP1β NM_002984.2 (SEQ ID NO:12) TGFβ1 NM_000660.4 (SEQ ID NO:13) TIMP-1 NM_003254.2 (SEQ ID NO:14) - It will be apparent from the preceding description that the diagnostic methods of the present invention may involve a degree of quantification to determine levels biomarkers in patient samples. Such quantification is readily provided by the inclusion of appropriate control samples.
- In one embodiment, internal controls are included in the methods of the present invention. A preferred internal control is one or more samples taken from one or more healthy individuals.
- In the present context, the term "healthy individual" shall be taken to mean an individual who is known not to suffer from colorectal cancer, such knowledge being derived from clinical data on the individual, including, but not limited to, a different diagnostic assay to that described herein.
- As will be known to those skilled in the art, when internal controls are not included in each assay conducted, the control may be derived from an established data set.
- Data pertaining to the control subjects are preferably selected from the group consisting of:
- 1. a data set comprising measurements of the presence or level of expression of biomarkers for a typical population of subjects known to have colorectal cancer;
- 2. a data set comprising measurements of the presence or level of biomarkers for the subject being tested wherein said measurements have been made previously, such as, for example, when the subject was known to be healthy or, in the case of a subject having colorectal cancer, when the subject was diagnosed or at an earlier stage in disease progression;
- 3. a data set comprising measurements of the presence or level of biomarkers for a healthy individual or a population of healthy individuals; and
- 4. a data set comprising measurements of the presence or level of biomarkers for a normal individual or a population of normal individuals.
- In the present context, the term "typical population" with respect to subjects known to have colorectal cancer shall be taken to refer to a population or sample of subjects diagnosed with colorectal cancer that is representative of the spectrum of colorectal cancer patients. This is not to be taken as requiring a strict normal distribution of morphological or clinicopathological parameters in the population, since some variation in such a distribution is permissible. Preferably, a "typical population" will exhibit a spectrum of colorectal cancer at different stages of disease progression. It is particularly preferred that a "typical population" exhibits the expression characteristics of a cohort of subjects as described herein.
- The term "normal individual" shall be taken to mean an individual that does not express a biomarker, or expresses a biomarker at a low level in a sample. As will be known to those skilled in the art, data obtained from a sufficiently large sample of the population will normalize, allowing the generation of a data set for determining the average level of a particular biomarker.
- Those skilled in the art are readily capable of determining the baseline for comparison in any diagnostic assay of the present invention without undue experimentation, based upon the teaching provided herein.
- Compounds that bind a biomarker when used diagnostically may be linked to a diagnostic reagent such as a detectable label to allow easy detection of binding events in vitro or in vivo. Suitable labels include radioisotopes, dye markers or other imaging reagents for detection and/or localisation of target molecules. Compounds linked to a detectable label can be used with suitable in vivo imaging technologies such as, for example, radiology, fluoroscopy, nuclear magnetic resonance imaging (MRI), CAT-scanning, positron emission tomography (PET), computerized tomography etc.
- The diagnostic methods of the present invention are able to diagnose or detect colorectal cancer with a sensitivity and specificity that is at least comparable to FOBT, or greater. As would be understood by the person skilled in the art, sensitivity refers to the proportion of actual positives in the diagnostic test which are correctly identified as having colorectal cancer. Specificity measures the proportion of negatives which are correctly identified as not having colorectal cancer. In one embodiment, the methods of the invention are able to diagnose or detect colorectal cancer with a sensitivity of at least 50%, 60% or 66%, or at least 77%, 80%, 83%, 85%, 86%, 87%, 88%, 89%, 90%, or at least 93%. In another embodiment, the methods of the invention are able to diagnose or detect colorectal cancer with a sensitivity of at least 80%, or at least 85% or at least 90%, or at least 95%.
- In one embodiment, the methods of the invention are able to diagnose or detect colorectal cancer with a specificity of at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% or at least 95%.
- Advantageously, the methods of the present invention are able to detect colorectal cancer at all of the Dukes Stages with greater sensitivity than the FOBT. In Dukes Stage A, the tumor has penetrated into, but not through, the bowel wall. In Dukes Stage B, the tumor has penetrated through the bowel wall but there is not yet any lymph node involvement. In Dukes Stage C, the cancer involves regional lymph nodes. In Dukes Stage D, there is distant metastasis, for example, to the liver or lung. In one embodiment, the methods of the present invention are able to diagnose or detect colorectal cancer at any Dukes Stage with a sensitivity of at least 80%.
- As known to the skilled person, there are other systems for staging cancer that are know in the art. One example is the TMN Classification of Malignant Tumors (TNM) that is used by the American Joint Committee on Cancer (AJCC: Colon and rectum. in Edge et al., eds; AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer, 2010, pp:143-164). Another example is the Modified Astler-Coller classification (MAC).
- Accordingly, the skilled person will appreciate that the Dukes Stages correspond to certain TNM Classifications. For example, Dukes Stage A corresponds to T1, T2, N0 and M0; Dukes Stage B corresponds to T3, T4a, T4b, N0 and M0; and Dukes Stage C corresponds to i) T1-T2, N1/N1c, M0; ii) T1, N2a and M0; iii) T3-T4a, N1/N1c and M0; iv) T2-T3, N2a and M0; v) T1-T2, N2b and M0; vi) T4a, N2a and M0; vii) T3-T4a, N2b and M0; and viii) T4b, N1-N2 and M0. Thus, the skilled person will understand that reference to a Dukes Stage as used herein includes reference to the corresponding TMN classification as known in the art.
- In one embodiment, biomarker polypeptide is detected in a patient sample, wherein the presence and/or level of the polypeptide in the sample is indicative of colorectal cancer. For example, the method may comprise contacting a biological sample derived from the subject with a compound capable of binding to a biomarker polypeptide, and detecting the formation of complex between the compound and the biomarker polypeptide. The term "biomarker polypeptide" as used herein includes fragments of biomarker polypeptides, including for example, immunogenic fragments and epitopes of the biomarker polypeptide.
- In one embodiment, the compound that binds the biomarker is an antibody.
- The term "antibody" as used herein includes intact molecules as well as molecules comprising or consisting of fragments thereof, such as, for example Fab, F(ab')2, Fv and scFv, as well as engineered variants including diabodies, triabodies, mini-bodies and single-domain antibodies which are capable of binding an epitopic determinant. Thus, antibodies may exist as intact immunoglobulins, or as modifications in a variety of forms.
- In another embodiment, an antibody to a biomarker polypeptide is detected in a patient sample, wherein the presence and/or level of the antibody in the sample is indicative of colorectal cancer.
- Preferred detection systems contemplated herein include any known assay for detecting proteins or antibodies in a biological sample isolated from a human subject, such as, for example, SDS/PAGE, isoelectric focussing, 2-dimensional gel electrophoresis comprising SDS/PAGE and isoelectric focussing, an immunoassay, flow cytometry e.g. fluorescence-activated cell sorting (FACS), a detection based system using an antibody or non-antibody compound, such as, for example, a small molecule (e.g. a chemical compound, agonist, antagonist, allosteric modulator, competitive inhibitor, or non-competitive inhibitor, of the protein). In accordance with these embodiments, the antibody or small molecule may be used in any standard solid phase or solution phase assay format amenable to the detection of proteins. Optical or fluorescent detection, such as, for example, using mass spectrometry, MALDI-TOF, biosensor technology, evanescent fiber optics, or fluorescence resonance energy transfer, is clearly encompassed by the present invention. Assay systems suitable for use in high throughput screening of mass samples, e.g. a high throughput spectroscopy resonance method (e.g. MALDI-TOF, electrospray MS or nano-electrospray MS), are also contemplated. Another suitable protein detection technique involves the use of Multiple Reaction Monitoring (MRM) in LC-MS (LC/MRM-MS) (Anderson and Hunter, 2006).
- Immunoassay formats are particularly suitable, e.g., selected from the group consisting of, an immunoblot, a Western blot, a dot blot, an enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), enzyme immunoassay. Modified immunoassays utilizing fluorescence resonance energy transfer (FRET), isotope-coded affinity tags (ICAT), matrix-assisted laser desorption/ionization time of flight (MALDI-TOF), electrospray ionization (ESI), biosensor technology, evanescent fiber-optics technology or protein chip technology are also useful.
- Any suitable technique that allows for the qualitative and/or quantitative assessment of the level of a biomarker polynucleotide in a sample may be used. The terms "nucleic acid molecule" or "polynucleotide" as used herein refer to an oligonucleotide, polynucleotide or any fragment thereof.
- Comparison may be made by reference to a standard control, or to a control level that is found in healthy tissue. For example, levels of a transcribed gene can be determined by Northern blotting, and/or RT-PCR. With the advent of quantitative (real-time) PCR, quantitative analysis of gene expression can be achieved by using appropriate primers for the gene of interest. The nucleic acid may be labelled and hybridised on a gene array, in which case the gene concentration will be directly proportional to the intensity of the radioactive or fluorescent signal generated in the array.
- Methods for direct sequencing of nucleotide sequences are well known to those skilled in the art and can be found for example in Ausubel et al., eds., Short Protocols in Molecular Biology, 3rd ed., Wiley, (1995) and Sambrook et al., Molecular Cloning, 3rd ed., Cold Spring Harbor Laboratory Press, (2001). Sequencing can be carried out by any suitable method, for example, dideoxy sequencing, chemical sequencing or variations thereof. Direct sequencing has the advantage of determining variation in any base pair of a particular sequence.
- Other PCR methods that may be used in carrying out the invention include hybridization based PCR detection systems, TaqMan assay (
US 5,962,233 ) and the molecular beacon assay (US 5,925,517 ). - The nucleic acid may be separated from the sample for testing. Suitable methods will be known to those of skill in the art. For example, RNA may be isolated from a sample to be analysed using conventional procedures, such as are supplied by QIAGEN technology. This RNA is then reverse-transcribed into DNA using reverse transcriptase and the DNA molecule of interest may then be amplified by PCR techniques using specific primers.
- Diagnostic procedures may also be performed directly upon patient samples. Hybridisation or amplification assays, such as, for example, Southern or Northern blot analysis, immunohistochemistry, single-stranded conformational polymorphism analysis (SSCP) and PCR analyses are among techniques that are useful in this respect. If desired, target or probe nucleic acid may be immobilised to a solid support such as a microtitre plate, membrane, polystyrene bead, glass slide or other solid phase.
- The present invention provides kits for the diagnosis or detection of colorectal cancer. Such kits may be suitable for detection of nucleic acid species, or alternatively may be for detection of a polypeptide gene product, as discussed above.
- For detection of polypeptides, antibodies will most typically be used as components of kits. However, any agent capable of binding specifically to a biomarker gene product will be useful in this aspect of the invention. Other components of the kits will typically include labels, secondary antibodies, substrates (if the gene is an enzyme), inhibitors, co-factors and control gene product preparations to allow the user to quantitate expression levels and/or to assess whether the diagnosis experiment has worked correctly. Enzyme-linked immunosorbent assay-based (ELISA) tests and competitive ELISA tests are particularly suitable assays that can be carried out easily by the skilled person using kit components.
- Optionally, the kit further comprises means for the detection of the binding of an antibody to a biomarker polypeptide. Such means include a reporter molecule such as, for example, an enzyme (such as horseradish peroxidase or alkaline phosphatase), a dye, a radionucleotide, a luminescent group, a fluorescent group, biotin or a colloidal particle, such as colloidal gold or selenium. Preferably such a reporter molecule is directly linked to the antibody.
- In yet another embodiment, a kit may additionally comprise a reference sample. In one embodiment, a reference sample comprises a polypeptide that is detected by an antibody. Preferably, the polypeptide is of known concentration. Such a polypeptide is of particular use as a standard. Accordingly, various known concentrations of such a polypeptide may be detected using a diagnostic assay described herein.
- For detection of nucleic acids, such kits may contain a first container such as a vial or plastic tube or a microtiter plate that contains an oligonucleotide probe. The kits may optionally contain a second container that holds primers. The probe may be hybridisable to DNA whose altered expression is associated with colorectal cancer and the primers are useful for amplifying this DNA. Kits that contain an oligonucleotide probe immobilised on a solid support could also be developed, for example, using arrays (see supplement of issue 21(1) Nature Genetics, 1999).
- For PCR amplification of nucleic acid, nucleic acid primers may be included in the kit that are complementary to at least a portion of a biomarker gene as described herein. The set of primers typically includes at least two oligonucleotides, preferably four oligonucleotides, that are capable of specific amplification of DNA. Fluorescent-labelled oligonucleotides that will allow quantitative PCR determination may be included (e.g. TaqMan chemistry, Molecular Beacons). Suitable enzymes for amplification of the DNA, will also be included.
- Control nucleic acid may be included for purposes of comparison or validation. Such controls could either be RNA/DNA isolated from healthy tissue, or from healthy individuals, or housekeeping genes such as β-actin or GAPDH whose mRNA levels are not affected by colorectal cancer.
- In order to develop a panel of biomarkers suitable for diagnosing or detecting colorectal cancer, the present inventors have analysed numerous biomarkers in a statistical model. Such an improvement in the performance of a test is sometimes referred to as the "in-sample" performance. A fair evaluation of a test requires its assessment using out-of-sample subjects, that is, subjects not included in the construction of the initial predictive model. This is achieved by assessing the test performance using cross validation.
- Tests for stastical significance include linear and non linear regression, including ANOVA, Kruskal-Wallis, Wilcoxon, Mann-Whitney and odds ratio, Baysian probability algorithms. As the number of biomarkers measured increases however, it can be generally more convenient to use a more sophisticated technique such as Random Forests, simple logistic, Bayes Net to name a few.
- For example, Bayesian probability may be adopted. In this circumstance a 10-fold cross-validation can be used to estimate the "out-of-sample" performance of the models in question. For each combination of biomarkers under consideration, the data can be divided randomly into 10 sub-samples, each with similar proportions of healthy subject and subjects at each stage of disease. In turn, each subsample can be excluded, and a logistic model built using the remaining 90% of the subjects. This model can then be used to estimate the probability of cancer for the excluded sub-sample, providing an estimate of "out-of-sample" performance. By repeating this for the remaining 9 subsamples, "out-of-sample" performance can be estimated from the study data itself. These out-of sample predicted probabilities can then be compared with the actual disease status of the subjects to create a Receiver Operating Characteristic (ROC) Curve, from which the cross-validated sensitivity at 95% specificity may be estimated.
- Each estimate of "out-of-sample" performance using cross-validation (or any other method), whilst unbiased, has an element of variability to it. Hence a ranking of models (based on biomarker combinations) can be indicative only of the relative performance of such models. However a set of biomarkers which is capable of being used in a large number of combinations to generate a diagnostic test as demonstrated via "out-of-sample" performance evaluations, almost certainly contains within itself combinations of biomarkers that will withstand repeated evaluation.
- Many different combinations can qualify as diagnostic tests which prove useful and cost effective and have acceptable sensitivity for a given specificity. As an example, consider the five biomarkers: IL-8, IGFBP2, MAC2BP, M2PK and DKK-3. A model discriminating subjects with cancer from healthy controls can be as follows:
- Here p represents the probability that a person has colorectal cancer. Each Ci is the logarithm of concentration biomarker i in the plasma (or serum) of a person. Each beta (β) is a coefficient applying to that biomarker in the concentration units in which it is measured - β0 is an "offset" or "intercept". This linear logistic model is common to all results presented herein, but is far from the only way in which a combination of biomarker concentrations may be modelled to predict the probability of cancer.
- Other non linear or linear logistic algorithms that would be equally applicable include Random Forest, ANOVA, t- Test, Fisher analysis, Support Vector Machine, Linear Models for MicroArray data (LIMMA) and/or Significance Analyses of Microarray Data (SAM), Best First, Greedy Stepwise, Naive Bayes, Linear Forward Selection, Scatter Search, Linear Discriminant Analysis (LDA), Stepwise Logistic Regression, Receiver Operating Characteristic and Classification Trees (CT).
- Thus, in light of the teachings of the present specification, the person skilled in the art will appreciate that the sensitivity and specificity of a test for diagnosing colorectal cancer may be modulated by selecting a different combination of the biomarkers as described herein
- It will be apparent from the discussion herein that knowledge-based computer software and hardware for implementing an algorithm also form part of the present invention. Such computer software and/or hardware are useful for performing a method of diagnosing or detecting colorectal cancer according the invention. Thus, the present invention also provides software or hardware programmed to implement an algorithm that processes data obtained by performing the method of the invention via a multivariate analysis to provide a disease score and provide or permit a diagnosis or detection of colorectal cancer and/or determine progression or status of a colorectal cancer or determine whether or not a colorectal cancer has progressed or determine whether or not a subject is responding to treatment for colorectal cancer in accordance with the results of the disease score in comparison with predetermined values.
- In one example, a method of the invention may be used in existing knowledge-based architecture or platforms associated with pathology services. For example, results from a method described herein are transmitted via a communications network (e.g. the internet) to a processing system in which an algorithm is stored and used to generate a predicted posterior probability value which translates to the score of disease probability or risk of recurrence or metastasis or responsiveness to treatment which is then forwarded to an end user in the form of a diagnostic or predictive report.
- The method of the invention may, therefore, be in the form of a kit or computer-based system which comprises the reagents necessary to detect the concentration of the biomarkers and the computer hardware and/or software to facilitate determination and transmission of reports to a clinician.
- The assay of the present invention permits integration into existing or newly developed pathology architecture or platform systems. For example, the present invention contemplates a method of allowing a user to determine the status of a subject with respect to colorectal cancer, the method including:
- (a) receiving data in the form of levels at least two biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1 in a readily obtained sample, optionally in combination with another marker of colorectal cancer;
- (b) processing the subject data via multivariate analysis (for example, regression analysis) to provide a disease score;
- (c) determining the status of the subject in accordance with the results of the disease score in comparison with predetermined values; and
- (d) transferring an indication of the status of the subject to the user via the communications network reference to the multivariate analysis includes an algorithm which performs the multivariate analysis function.
- In one embodiment, the method for diagnosing or detecting colorectal cancer of the invention may be performed by taking a blood sample from a patient and determining the presence and/or level of any one or more of the biomarkers as described herein. If desired, the measurements may be made, for example, on a biochip so that a single analysis can be used to measure the presence and/or level of multiple biomarkers. The results of this analysis may then be inputted into into a computer program that subjects them to linear regression analysis. The computer could also contain information as to control values or expected ranges, or the clinician, nurse, medcal administrator or general practitioner could input such data. This analysis wold then provide a score or likelihood of having colorectal cancer. If a second test for the patient is performed, the regression analysis may indicate a change in the score, thus indicating that the patient's disease has progressed or worsened.
- Further aspects of the invention are as follows:
- 1. A method for diagnosing or detecting colorectal cancer in a subject, the method comprising:
- i) determining the presence and/or level of at least two biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1 in a sample from the subject,
wherein the presence and/or level of the two biomarkers is indicative of colorectal cancer.
- i) determining the presence and/or level of at least two biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1 in a sample from the subject,
- 2. The method of
aspect 1, wherein the method comprises determining the presence and/or level of two biomarkers selected from M2PK, EpCam, IL-13, DKK-3, IL-8 and IGFBP2. - 3. The method of
aspect 1 or aspect 2, wherein the method comprises determining the presence and/or level of expression of at least three of the biomarkers. - 4. The method of
aspect 3, wherein the three biomarkers are selected from M2PK, EpCam, IL-13, DKK-3, IL-8, IGFBP2, MIP1β, TGFβ1 and MAC2BP. - 5. The method of aspect 4, wherein the method comprises determining the presence and/or level of three biomarkers, wherein the three biomarkers are:
- i) DKK-3, M2PK, and IGFBP2;
- ii) M2PK, IGFBP2, and EpCAM;
- iii) M2PK, MIP1β, and TGFβ1; or
- iv) IL-8, IL-13, and MAC2BP.
- 6. The method of any one of the preceding aspects, wherein the method comprises determining the presence and/or level of expression of at least four of the biomarkers.
- 7. The method of
aspect 6, wherein the method comprises determining the presence and/or level of four biomarkers, wherein the four biomarkers are:- i) DKK-3, M2PK, MAC2BP, and IGFBP2;
- ii) IL-8, IL-13, MAC2BP, and EpCam;
- iii) DKK3, M2PK, TGFβ1, and TIMP-1;
- iv) M2PK, MIP1β, IL-13, and TIMP-1; or
- v) IL-8, MAC2BP, IGFBP2, and EpCam.
- 8. The method of any one of the preceding aspects, wherein the method comprises determining the presence and/or level of at least five of the biomarkers.
- 9. The method of any one of the preceding aspects, wherein the method comprises determining the presence and/or level of at least six of the biomarkers.
- 10. The method of any one of the preceding aspects, wherein the method comprises determining the presence and/or level of at least seven of the biomarkers.
- 11. The method of any one of the preceding aspects, wherein the method comprises determining the presence and/or level of at least eight of the biomarkers.
- 12. The method of any one of the preceding aspects, wherein the method comprises determining the presence and or level of at least nine of the biomarkers.
- 13. The method of any one of the preceding aspects, wherein the method comprises determining the presence and/or level of at least ten of the biomarkers.
- 14. The method of any one of the preceding aspects, wherein the method comprises detecting the presence and/or level of least one additional biomarker selected from IGF-I, IGF-II, IGF-BP2, Amphiregulin, VEGFA, VEGFD, MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2, ENA-78, MCP-1, MIP-1β, IFN-γ, IL-10, IL-13, IL-1β, IL-4, IL-8, IL-6, MAC2BP, Tumor M2 pyruvate kinase, M65, OPN, DKK-3, EpCam, TGFβ-1, and VEGFpan.
- 15. The method of any one of the preceding aspects, wherein the method diagnoses or detects colorectal cancer with a sensitivity of at least 50%.
- 16. The method of aspect 15, wherein the method diagnoses or detects colorectal cancer with a sensitivity of at least 66%.
- 17. The method of aspect 16, wherein the method diagnoses or detects colorectal cancer with a sensitivity of at least 77%.
- 18. The method of any one of the preceding aspects, wherein the method diagnoses or detects Dukes Stage A colorectal cancer with a sensitivity of at least 50% and a specificity of at least 95%.
- 19. The method of any one of the preceding aspects, wherein the method diagnoses or detects Dukes Stage A colorectal cancer with a sensitivity of at least 60% and a specificity of at least 80%.
- 20. The method of any one of the preceding aspects, wherein the method diagnoses or detects Dukes Stage A colorectal cancer with a sensitivity of at least 50% and a specificity of at least 90%.
- 21. The method of any one of the preceding aspects, wherein the method comprises contacting the sample with at least one compound that binds a biomarker polypeptide.
- 22. The method of aspect 21, wherein the compound is detectably labelled.
- 23. The method of aspect 21 or aspect 22, wherein the compound is an antibody.
- 24. The method of any one of aspects 21 to 23, wherein the compound is bound to a solid support.
- 25. The method of any one of
aspects 1 to 20, wherein the biomarkers are polynucleotides. - 26. The method of any one of the preceding aspects, wherein the method comprises:
- i) determining the presence and/or level of the biomarkers in the sample from the subject; and
- ii) comparing the presence and/or level of the biomarkers to a control, wherein a presence and/or level in the sample that is different to the control is indicative of colorectal cancer.
- 27. The method of any one of the preceding aspects, wherein the sample comprises blood, plasma, serum, urine, platelets, magakaryocytes or faeces.
- 28. A method of treatment comprising:
- (i) diagnosing or detecting colorectal cancer according to the method of the invention; and
- (ii) administering or recommending a therapeutic for the treatment of colorectal cancer.
- 29. A method for monitoring the efficacy of treatment of colorectal cancer in a subject, the method comprising treating the subject for colorectal cancer and then detecting the presence and/or level of at least two biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1 in a sample from the subject, wherein an absence of and/or reduction in the level of expression of the polypeptides after treatment when compared to before treatment is indicative of effective treatment.
- 30. An array of at least two compounds for the diagnosis or detection of colorectal cancer, wherein each of the compounds binds a different biomarker polypeptide selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1.
- 31. A kit for diagnosing or detecting colorectal cancer in a subject, the kit comprising two compounds that each binds a different biomarker polypeptide selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1.
- A collection of plasma and serum samples was taken and processed from a cohort of colorectal cancer patients (Dukes Stages A-D) that were being treated at several hospitals.
- Blood was also collected and processed from a group of about 50 healthy volunteers over the age of 65 and from a group of 15 over the age of 50.
- Four separate studies were undertaken with slightly different biomarkers.
Study 1 looked at 52 cancer samples and 50 controls, study 2 looked at 55 cancer samples and 53 controls,study 3 and 4 looked at 96 cancer samples and 50 controls. Instudy 2, 3 and 4 the patients were age and gender matched across Dukes Stages, see Table 2 for summary statistics.Table 2. Characteristics of normal volunteers and colorectal cancer patients used in studies 2, 3 and 4.Controls Cancers n=50 n=96 Gender male 25 48 female 25 48 Mean Age (yr) 68 68 Dukes stage A 22 B 30 C 30 D 14 Tumour site colon 73 rectum 17 unknown 6 Proximal (includes caecum, ascending, hepatic flexure and transverse colon) 43 Distal (includes splenic flexure, descending, sigmoid and rectum) 47 - Analysis of biomarkers was done with commercial kits and sourced antibodies (DSL, R&D Duoset, Calbiotech, Millipore, Abnova, Genway, Peviva, Schebo, Bender) and using ELISA or Luminex assays.
- Results for each assay were analysed using the statistical software packages Prism and "R". Individual performance of markers was evaluated using the non-parametric Mann-Whitney t-test and individual receiver operator characteristic (ROC) curves were generated.
- Logistic regression and related modelling strategies were used to find combinations of biomarkers that best separated controls and colorectal cancer patients. Four separate studies were performed with the same samples/aliquots. The results of each of these is given below.
- Biomarkers chosen to be measured in
Study Table 3. Biomarkers analysed in studies. Study 1Study 2 Study 3IGF-I IGF-BP2 IGF-BP2 (DSL) IGF-II IGF-II IGF-II IGF-BP2 IGF-BP3 IFNg IGF-BP3 Her2 TNFa BTC VegFA IL-10 Amphiregulin VegFC IL-6 VegFA VegFD GM-CSF VegFC TIMP-1 IL-12 VegFD TIMP-2 IL-13 MMP-2 MMP-1 IL-8 MMP-7 MMP-2 IL-4 MMP-9 MMP-3 Il-2 TIMP-2 MMP-7 IL-1b Her2 MMP-8 MMP-1 MMP-12 MMP-2 MMP-13 MMP-3 ENA-78 MMP-7 MCP-1 MMP-8 MIP-1beta MMP-9 GM-CSF ENA-78 IFN-gamma MIP-1alpha IL-10 MIP-1beta IL-12 MCP-1 IL-13 Mac-2BP IL-1beta TIMP-1 IL-2 TIMP-2 IL-4 Gro-alpha IL-6 Tumour M2 pyruvate kinase IL-8 M30-apoptosense TNF-alpha M65 Cripto Trail-R2 P-cadherin OPN Dkk-3 EpCam TGFbeta1 REG IV CEA DcR3 CA19.9 Amphiregulin CEACAM6 VegFA pan VegFA165b Spondin-2 survivin - To find combinations of biomarkers that best separated controls and colorectal cancer patients, forward variable selection with Bayesian Information Criteria to penalize log-likelihood to prevent over-fitting was adopted. To estimate the likely performance of the panel of biomarkers on an independent dataset, "N-Fold" or "leave-one-out" cross validation was used. In this procedure one observation at a time was excluded whilst the entire model fitting algorithm was applied to the remaining observations.
- The resulting model was then used to estimate the probability that the excluded observation is a case. This was repeated for each observation in the dataset. In this way each observation in turn acted as an independent test of the model-building algorithm. The resulting dataset consisting of cases and controls each with an "independently predicted" case probability can then be compared with the original model. The ability to choose from numerous biomarkers and weight them appropriately allows a search strategy which optimises performance in regions of interest on the ROC curve. The cost of poor specificity is large numbers of unnecessary colonoscopies.
- In
study 3, 48 potential biomarkers were evaluated to select a candidate panel of colorectal cancer biomarkers, using block randomization within plates to avoid bias. From this list of 48 only 42 showed measurable levels. Individually 14 biomarkers showed significant difference between controls and CRC as assessed by t-tests; (IGFII, IGFBP2, IL-8, IL-6, MMP-1, MMP-7, s90/Mac2BP, M2PK, EpCam, TIMP-1 (serum and plasma), M65, OPN, TGFβ1, VEGFpan. As expected, none had sufficient sensitivity or specificity to be useful as a biomarker by itself (not shown). However, using a variety of modelling strategies, including use of logarithmic values, several different panels of biomarkers were found that exceeded the performance of FOBT especially for early to late stage disease. -
Figure 1 shows the results from a 7 biomarker panel which included IL8 (serum), IL-13 (serum), EpCAM (plasma), M2PK (plasma), IGFBP2 (serum) and Mac2BP (serum) and which was cross validated to predict its performance on independent samples. -
- provided good performance at high specificity and was robust under cross validation. The coefficients estimated to give the best model for this biomarker combination in plasma are listed in Table 4. Performance statistics are provided in Table 5. This performance exceeds that quoted for FOBT (sensitivity 65.8%,
specificity 95%) (Morikawa et al., 2005).Table 4. Coefficients for the biomarker combination. Biomarker Measured in Concentration Units Coefficient Intercept NA NA -37.74 IL-8 serum pg/mL 1.07 IL-13 serum pg/mL -0.28 EpCAM plasma pg/mL -0.33 M2PK plasma units/mL 1.40 IGFBP2 serum ng/mL 1.99 Mac2BP serum ng/mL 2.39 MIP1beta Serum Pg/ml -1.19 Table 5. Performance of the 7 biomarker model and cross-validation. Model estimate Cross validation Area Under the ROC Curve (AUC) 0.91 0.86 Sensitivity at 80% specificity 0.84 0.78 Sensitivity at 90% specificity 0.81 0.69 - This model was also applied separately to patients from each stage of colorectal cancer (Dukes Stage A, B, C, D) and shown to perform equally well within each stage (
Figure 2 ). The AUCs were 0.88-0.93 and were almost equally good at discriminating all Stages of colorectal cancer. The model shows the highest sensitivity of 90% at 90% specificity for Stage C and the lowest sensitivity of 73% at 90% specificity for Stage B (Table 6).Table 6. Performance of the Model by Dukes Stage Stage A Stage B Stage C Stage D Area Under the ROC Curve (AUC) 0.89 0.88 0.93 0.91 Sensitivity at 80% specificity 0.82 0.77 0.90 0.93 Sensitivity at 90% specificity 0.77 0.73 0.90 0.86 - In study 4, 10 biomarkers were remeasured in the same cohort as
Study 3. Blood was collected from 96 colorectal cancer patients and 50 normal subjects (the controls). In this study the focus was on 10 biomarkers, namely IGFBP2, IL8, IL13,Mac2BP, M2PK, Dkk3, EpCam, TGFbeta1, TIMP-1, MIP1beta. Assays were performed as described previously. Both serum and plasma levels of each of the biomarkers were measured and compared with control values. - When modelled in pairs (two markers), a total of 5 pairs (out of a possible 45 combinations selected from the list of 10 biomarkers above) could be shown to produce a sensitivity above 52% at a specificity of 95%. See Table 7 and
Figure 3 .Table 7. Biomarker Pairs Producing Useful Screening Tests on Cross-Validation. Biomarker 1Biomarker 2 Estimated In-Sample (Test) Sensitivity at 95% Specificity Estimated Out-of-Sample (Cross-Validated) Sensitivity at 95% Specificity M2PK EpCAM 58.3% 58.3% M2PK IL13 56.3% 57.3% Dkk3 M2PK 55.2% 55.2% M2PK IL8 60.4% 54.2% M2PK IGFBP2 58.3% 52.1% - In analysing combinations of three to ten of the nominated biomarkers, there are 968 possible combinations. The 968 combinations of between 3 and 10 biomarkers consist of the 120 combinations of 3 marker; 210 combinations of 4 markers; 252 combinations of 5 markers; 210 combinations of 6 markers; 120 combinations of 7 markers; 45 combinations of 8 markers; 10 combinations of 9 markers and the single combination that includes all 10 biomarkers. When they were modelled using a linear logistic model, and then tested via 10-fold cross validation, about half of the 968 combinations had a sensitivity of 50% at a specificity of 95%, see
Figure 4 which shows the results for a three biomarker combination. More than half of these combinations would have a specificity of 90% and a sensitivity of 50%. -
Figure 5 shows all 485 of the estimated out-of sample (10-fold cross-validated) ROC curves for tests out of a total possible 968 models based on all possible combinations of 3 to 10 of the biomarkers. Note that many individual segments of the 485 ROC curves are coincident, due to as each horizontal segment represents one control and each vertical segment one case. In this instance 50.1% of the combinations have exceeded the 50% sensitivity, 95% specificity, The best estimated "out-of sample" performance is a sensitivity of 76% at 95% specificity. Repeating the cross-validation will select a different set of models - the sensitivity of any one combination may vary by 10% at 95% specificity due to random sampling - but result in a similar proportion of useful "useful screening tests". Precise validation of individual models requires repeated experiments and larger sample sizes. -
Figure 6 shows how many of the 485 combinations with 50% sensitivity, 95% specificity, include any given biomarker. At the high end, 432 of the chosen "useful" combinations include M2PK. At the low end 227 of the chosen "useful" combinations include MIP1beta. This high representation of all 10 biomarkers in "useful" models shows the unity and self-complementarity of the selection of these 10 biomarkers. -
Figures 7 to Figure 11 demonstrate some of the results from this last study (Study 4) for combinations of 5 and 7 biomarkers, including a model where the samples are either from plasma or serum cluster.Figure 11 demonstrates the validity of the choice of three biomarkers (DKK-3, M2PK and IGFBP2) at different stages of the disease progression. The data indicates that at Stage A if the three markers are used, the test still will achieve a signifcant senstivity (64%) at 95 % specificity which is comparable to the sensitivity achieved at late stage disease, 79%). That is the biomarker panel of three will pick up early disease states allowing early detection. - Tables 8 to 16 list results from various combinations of various biomarker panel sets. Depending on the linear regression that is used, as well as the cohort control and other factors such as sample derivation and assay kit technique, there may be a variation on the actual figures or order of the markers. Regardless, many of these combinations will achieve good selectivity at high specificities so as to be useful for diagnosing or detecting colorectal cancer at any stage of the disease progression.
Table 8. Combination of three biomarkers in serum that equal or exceed 50% sensitivity at 95% specificity. BM1 BM2 BM3 Test Sensitivity at 95% Specificity Cross Validated Sensitivity at 95% Specificity Dkk3 M2PK IGFBP2 72.9% 70.8% Dkk3 M2PK IL8 62.5% 61.5% M2PK IL13 IGFBP2 65.6% 61.5% M2PK IGFBP2 EpCAM 63.5% 61.5% M2PK IL8 IGFBP2 65.6% 60.4% M2PK IL8 IL13 61.5% 58.3% M2PK MIP1beta IL13 55.2% 57.3% M2PK IL8 Mac2BP 59.4% 57.3% M2PK MIP1beta TGFbeta1 57.3% 56.3% M2PK IL8 EpCAM 64.6% 56.3% Dkk3 M2PK IL13 59.4% 55.2% Dkk3 M2PK EpCAM 56.3% 55.2% M2PK MIP1beta EpCAM 59.4% 55.2% M2PK IL8 TGFbeta1 58.3% 55.2% M2PK IL8 TIMP1 57.3% 55.2% TGFbeta1 Mac2BP TIMP1 54.2% 55.2% M2PK Mac2BP IGFBP2 58.3% 54.2% Dkk3 IL8 Mac2BP 55.2% 53.1% M2PK MIP1beta Mac2BP 52.1% 53.1% M2PK MIP1beta IGFBP2 57.3% 53.1% M2PK TIMP1 EpCAM 58.3% 53.1% M2PK MIP1beta IL8 56.3% 52.1% M2PK IL13 TIMP1 58.3% 52.1% Dkk3 M2PK Mac2BP 57.3% 51.0% Dkk3 M2PK TIMP1 55.2% 51.0% M2PK IL13 Mac2BP 58.3% 51.0% M2PK TGFbeta1 IGFBP2 52.1% 51.0% M2PK TGFbeta1 TIMP1 57.3% 51.0% M2PK TGFbeta1 Mac2BP 56.3% 50.0% IL8 IL13 Mac2BP 61.5% 50.0% IL8 TGFbeta1 Mac2BP 53.1% 50.0% M2PK MIP1beta TIMP1 49.0% 49.0% M2PK TGFbeta1 EpCAM 49.0% 47.9% IL8 IL13 IGFBP2 49.0% 47.9% IL8 Mac2BP IGFBP2 57.3% 47.9% Dkk3 M2PK MIP1beta 55.2% 46.9% TGFbeta1 Mac2BP IGFBP2 46.9% 46.9% Dkk3 Mac2BP IGFBP2 49.0% 45.8% M2PK IL13 EpCAM 50.0% 45.8% IL8 Mac2BP TIMP1 52.1% 45.8% IL13 Mac2BP IGFBP2 45.8% 44.8% Dkk3 IL8 TGFbeta1 41.7% 43.8% MIP1beta IL8 Mac2BP 42.7% 43.8% MIP1beta IL8 EpCAM 44.8% 43.8% IL8 TGFbeta1 EpCAM 46.9% 43.8% Dkk3 IL8 EpCAM 51.0% 42.7% IL8 IGFBP2 EpCAM 43.8% 42.7% M2PK Mac2BP TIMP1 51.0% 41.7% Table 9. Combination of four biomarkers including DKK-3 in serum that equal or exceed 50% sensitivity at 95% specificity. BM1 BM2 BM3 BM4 Test Sensitivity at 95% Specificity Cross Validated Sensitivity at 95% Specificity Dkk3 M2PK Mac2BP IGFBP2 68.8% 69.8% Dkk3 M2PK IL8 IL13 71.9% 68.8% Dkk3 M2PK IL8 EpCAM 70.8% 67.7% Dkk3 M2PK TGFbeta1 Mac2BP 67.7% 65.6% Dkk3 M2PK IL8 IGFBP2 69.8% 64.6% Dkk3 M2PK IL8 Mac2BP 69.8% 63.5% Dkk3 M2PK MIP1beta TGFbeta1 65.6% 61.5% Dkk3 M2PK IL8 TIMP1 68.8% 61.5% Dkk3 M2PK IL13 IGFBP2 63.5% 61.5% Dkk3 M2PK MIP1beta IL8 59.4% 60.4% Dkk3 M2PK IGFBP2 EpCAM 68.8% 60.4% Dkk3 M2PK MIP1beta IGFBP2 69.8% 59.4% Dkk3 M2PK TGFbeta1 IGFBP2 61.5% 59.4% Dkk3 M2PK IL13 Mac2BP 56.3% 58.3% Dkk3 M2PK TGFbeta1 TIMP1 65.6% 58.3% Dkk3 M2PK MIP1beta IL13 57.3% 57.3% Dkk3 IL8 Mac2BP IGFBP2 62.5% 56.3% Dkk3 M2PK IL8 TGFbeta1 65.6% 55.2% Dkk3 M2PK IL13 TIMP1 57.3% 55.2% Dkk3 M2PK Mac2BP TIMP1 57.3% 55.2% Dkk3 M2PK MIP1beta Mac2BP 57.3% 54.2% Dkk3 IL8 IL13 Mac2BP 61.5% 54.2% Dkk3 M2PK TGFbeta1 EpCAM 61.5% 53.1% Dkk3 M2PK IGFBP2 TIMP1 61.5% 53.1% Dkk3 M2PK IL13 TGFbeta1 63.5% 52.1% Dkk3 M2PK TIMP1 EpCAM 56.3% 52.1% Dkk3 IL8 Mac2BP TIMP1 57.3% 52.1% Dkk3 M2PK MIP1beta EpCAM 60.4% 51.0% Dkk3 TGFbeta1 Mac2BP TIMP1 59.4% 51.0% Table 10. Combination of four biomarkers including M2PK in serum that equal or exceed 50% sensitivity at 95% specificity. BM1 BM2 BM3 BM4 Test Sensitivity at 95% Specificity Cross Validated Sensitivity at 95% Specificity M2PK IL8 Mac2BP TIMP1 63.5% 65.6% M2PK Mac2BP IGFBP2 EpCAM 70.8% 65.6% M2PK IL8 IL13 Mac2BP 66.7% 64.6% M2PK IL8 TGFbeta1 Mac2BP 65.6% 64.6% M2PK MIP1beta IL13 IGFBP2 64.6% 62.5% M2PK IL8 IL13 TIMP1 64.6% 62.5% M2PK IL8 IL13 EpCAM 65.6% 62.5% M2PK IL13 Mac2BP IGFBP2 69.8% 62.5% M2PK MIP1beta IL8 IL13 63.5% 61.5% M2PK IL8 Mac2BP EpCAM 65.6% 61.5% M2PK IL13 IGFBP2 EpCAM 69.8% 61.5% M2PK MIP1beta IL8 TGFbeta1 58.3% 58.3% M2PK IL8 IL13 IGFBP2 67.7% 58.3% M2PK IL8 Mac2BP IGFBP2 61.5% 58.3% M2PK IL8 IGFBP2 EpCAM 64.6% 58.3% M2PK IL13 TGFbeta1 IGFBP2 64.6% 58.3% M2PK IL13 TGFbeta1 EpCAM 62.5% 58.3% M2PK IL13 IGFBP2 TIMP1 62.5% 58.3% M2PK TGFbeta1 Mac2BP TIMP1 62.5% 58.3% M2PK TGFbeta1 IGFBP2 EpCAM 61.5% 58.3% M2PK MIP1beta IL13 TIMP1 57.3% 57.3% M2PK MIP1beta TGFbeta1 TIMP1 58.3% 57.3% M2PK MIP1beta IGFBP2 EpCAM 65.6% 57.3% M2PK MIP1beta IL8 Mac2BP 54.2% 56.3% M2PK IL8 IL13 TGFbeta1 64.6% 56.3% M2PK IL8 TIMP1 EpCAM 62.5% 56.3% M2PK IL13 Mac2BP TIMP1 57.3% 56.3% M2PK TGFbeta1 Mac2BP IGFBP2 60.4% 56.3% M2PK IGFBP2 TIMP1 EpCAM 63.5% 56.3% M2PK MIP1beta IL8 TIMP1 57.3% 55.2% M2PK IL8 TGFbeta1 TIMP1 57.3% 55.2% M2PK MIP1beta IL13 Mac2BP 57.3% 54.2% M2PK MIP1beta IL8 EpCAM 62.5% 53.1% M2PK MIP1beta TIMP1 EpCAM 59.4% 52.1% M2PK IL13 TGFbeta1 TIMP1 64.6% 52.1% M2PK IL13 Mac2BP EpCAM 51.0% 52.1% M2PK MIP1beta IL13 TGFbeta1 57.3% 51.0% M2PK MIP1beta Mac2BP IGFBP2 57.3% 51.0% M2PK TGFbeta1 Mac2BP EpCAM 52.1% 51.0% M2PK TGFbeta1 TIMP1 EpCAM 59.4% 51.0% M2PK MIP1beta IL8 IGFBP2 52.1% 50.0% M2PK Mac2BP TIMP1 EpCAM 52.1% 50.0% M2PK MIP1beta TGFbeta1 Mac2BP 63.5% 49.0% M2PK MIP1beta IL13 EpCAM 50.0% 47.9% M2PK MIP1beta TGFbeta1 EpCAM 53.1% 47.9% M2PK IL13 TGFbeta1 Mac2BP 60.4% 46.9% M2PK MIP1beta TGFbeta1 IGFBP2 49.0% 44.8% Table 11. Combination of five biomarkers in serum that equal or exceed 50% sensitivity at 95% specificity. BM1 BM2 BM3 BM4 BM5 Test Sensitivity at 95% Specificity Cross Validated Sensitivity at 95% Specificity Dkk3 M2PK IL8 IL13 Mac2BP 74.0% 70.8% Dkk3 M2PK IL8 IL13 TIMP1 71.9% 70.8% M2PK TGFbeta1 Mac2BP IGFBP2 EpCAM 69.8% 70.8% Dkk3 M2PK MIP1beta IL8 IL13 71.9% 69.8% Dkk3 M2PK MIP1beta IGFBP2 EpCAM 71.9% 69.8% Dkk3 M2PK IL8 IGFBP2 EpCAM 78.1% 69.8% Dkk3 M2PK TGFbeta1 Mac2BP IGFBP2 68.8% 69.8% M2PK MIP1beta Mac2BP IGFBP2 EpCAM 69.8% 68.8% Dkk3 M2PK IL8 TGFbeta1 Mac2BP 70.8% 67.7% Dkk3 M2PK Mac2BP IGFBP2 EpCAM 70.8% 67.7% M2PK MIP1beta IL8 IL13 Mac2BP 66.7% 67.7% Dkk3 M2PK IL8 IL13 IGFBP2 70.8% 66.7% Dkk3 M2PK IL13 TGFbeta1 IGFBP2 68.8% 66.7% Dkk3 M2PK IL13 IGFBP2 EpCAM 66.7% 66.7% M2PK IL13 Mac2BP IGFBP2 EpCAM 71.9% 66.7% Dkk3 M2PK IL8 IL13 TGFbeta1 69.8% 65.6% Dkk3 M2PK IL8 Mac2BP TIMP1 67.7% 65.6% Dkk3 M2PK TGFbeta1 Mac2BP EpCAM 66.7% 65.6% M2PK IL8 IL13 TGFbeta1 Mac2BP 71.9% 65.6% M2PK IL8 IL13 TGFbeta1 IGFBP2 66.7% 65.6% M2PK IL8 TGFbeta1 Mac2BP IGFBP2 64.6% 65.6% M2PK IL8 TGFbeta1 Mac2BP EpCAM 69.8% 65.6% Dkk3 M2PK MIP1beta IL8 IGFBP2 66.7% 64.6% Dkk3 M2PK MIP1beta Mac2BP IGFBP2 70.8% 64.6% M2PK MIP1beta IL8 IL13 TIMP1 65.6% 64.6% M2PK MIP1beta IL8 TGFbeta1 Mac2BP 65.6% 64.6% M2PK IL8 IL13 Mac2BP EpCAM 76.0% 64.6% M2PK IL8 IL13 IGFBP2 EpCAM 72.9% 64.6% M2PK IL8 TGFbeta1 Mac2BP TIMP1 64.6% 64.6% M2PK IL8 Mac2BP IGFBP2 EpCAM 71.9% 64.6% Dkk3 M2PK IL13 TGFbeta1 TIMP1 68.8% 63.5% Dkk3 M2PK IGFBP2 TIMP1 EpCAM 67.7% 63.5% M2PK MIP1beta IL13 IGFBP2 EpCAM 67.7% 63.5% M2PK IL13 TGFbeta1 Mac2BP IGFBP2 66.7% 63.5% M2PK IL13 TGFbeta1 IGFBP2 EpCAM 70.8% 63.5% Dkk3 M2PK MIP1beta IL13 TGFbeta1 69.8% 62.5% Dkk3 M2PK IL8 IL13 EpCAM 65.6% 62.5% Dkk3 M2PK IL8 TGFbeta1 IGFBP2 70.8% 62.5% Dkk3 M2PK IL8 Mac2BP IGFBP2 69.8% 62.5% Dkk3 M2PK IL13 TGFbeta1 Mac2BP 68.8% 62.5% Dkk3 M2PK TGFbeta1 Mac2BP TIMP1 68.8% 62.5% Dkk3 M2PK TGFbeta1 TIMP1 EpCAM 67.7% 62.5% M2PK IL8 IL13 Mac2BP TIMP1 64.6% 62.5% M2PK IL8 IL13 IGFBP2 TIMP1 66.7% 62.5% M2PK IL13 IGFBP2 TIMP1 EpCAM 68.8% 62.5% Dkk3 M2PK MIP1beta IL13 IGFBP2 63.5% 61.5% Dkk3 M2PK IL8 TGFbeta1 TIMP1 64.6% 61.5% Table 12. Combination of seven biomarkers in serum that equal or exceed 50% sensitivity at 95% specificity. BM1 BM2 BM3 BM4 BM5 BM6 BM7 Test Sensitivity at 95% Specificity Cross Validated Sensitivity at 95% Specificity Dkk3 M2PK IL8 Mac2BP IGFBP2 TIMP1 EpCAM 78% 56% Dkk3 M2PK MIP1beta IL8 Mac2BP IGFBP2 EpCAM 76% 64% Dkk3 M2PK IL8 IL13 Mac2BP IGFBP2 TIMP1 73% 69% Dkk3 M2PK IL8 TGFbeta1 Mac2BP IGFBP2 TIMP1 72% 68% Dkk3 M2PK IL8 TGFbeta1 Mac2BP IGFBP2 EpCAM 71% 62% Dkk3 M2PK MIP1beta IL8 Mac2BP IGFBP2 TIMP1 70% 64% Dkk3 M2PK IL8 IL13 Mac2BP IGFBP2 EpCAM 70% 67% Dkk3 M2PK IL8 IL13 TGFbeta1 Mac2BP IGFBP2 69% 66% M2PK MIP1beta IL8 Mac2BP IGFBP2 TIMP1 EpCAM 69% 55% Dkk3 M2PK MIP1beta IL8 IL13 Mac2BP IGFBP2 67% 68% Dkk3 M2PK MIP1beta IL8 TGFbeta1 Mac2BP IGFBP2 67% 64% Dkk3 M2PK MIP1beta TGFbeta1 Mac2BP IGFBP2 TIMP1 65% 59% Dkk3 M2PK IL8 IL13 TGFbeta1 IGFBP2 TIMP1 65% 52% Dkk3 M2PK IL8 TGFbeta1 IGFBP2 TIMP1 EpCAM 64% 56% Dkk3 M2PK IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 64% 57% M2PK MIP1beta IL8 IL13 IGFBP2 TIMP1 EpCAM 64% 50% Dkk3 M2PK MIP1beta IL8 IL13 Mac2BP TIMP1 63% 55% Dkk3 M2PK MIP1beta IL8 TGFbeta1 IGFBP2 EpCAM 63% 58% Dkk3 M2PK MIP1beta IL13 TGFbeta1 Mac2BP IGFBP2 63% 53% Dkk3 M2PK IL8 IL13 TGFbeta1 Mac2BP TIMP1 63% 59% M2PK MIP1beta IL8 TGFbeta1 Mac2BP IGFBP2 EpCAM 63% 59% Dkk3 M2PK MIP1beta IL8 TGFbeta1 Mac2BP TIMP1 62% 51% Dkk3 M2PK MIP1beta IL8 IGFBP2 TIMP1 EpCAM 62% 56% Dkk3 M2PK MIP1beta IL13 Mac2BP IGFBP2 TIMP1 62% 39% Dkk3 M2PK IL8 IL13 TGFbeta1 TIMP1 EpCAM 62% 43% Dkk3 M2PK IL8 TGFbeta1 Mac2BP TIMP1 EpCAM 62% 50% Dkk3 MIP1beta IL8 IL13 Mac2BP IGFBP2 TIMP1 62% 55% Dkk3 MIP1beta IL8 Mac2BP IGFBP2 TIMP1 EpCAM 62% 47% M2PK MIP1beta IL8 IL13 Mac2BP IGFBP2 TIMP1 62% 56% M2PK IL8 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 62% 49% Dkk3 M2PK IL8 IL13 TGFbeta1 IGFBP2 EpCAM 60% 56% Dkk3 M2PK IL13 TGFbeta1 Mac2BP IGFBP2 EpCAM 60% 55% M2PK MIP1beta IL8 IL13 Mac2BP IGFBP2 EpCAM 60% 53% Table 13. Seven biomarker combinations with Sensitivity between 60% and 52 %. BM1 BM2 BM3 BM4 BM5 BM6 BM7 Test Sensitivity at 95% Specificity Cross Validated Sensitivity at 95% Specificity Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 EpCAM 59% 54% Dkk3 M2PK MIP1beta IL8 IL13 IGFBP2 EpCAM 59% 52% Dkk3 M2PK MIP1beta IL8 TGFbeta1 IGFBP2 TIMP1 59% 52% Dkk3 M2PK TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 59% 47% Dkk3 MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 59% 52% Dkk3 MIP1beta IL8 TGFbeta1 Mac2BP IGFBP2 TIMP1 59% 45% Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP 58% 41% Dkk3 M2PK MIP1beta IL8 TGFbeta1 TIMP1 EpCAM 58% 50% Dkk3 M2PK IL8 IL13 IGFBP2 TIMP1 EpCAM 58% 55% Dkk3 MIP1beta IL8 IL13 Mac2BP IGFBP2 EpCAM 58% 50% Dkk3 IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 58% 52% M2PK IL8 IL13 Mac2BP IGFBP2 TIMP1 EpCAM 58% 52% Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 IGFBP2 57% 49% Dkk3 M2PK MIP1beta IL8 IL13 TIMP1 EpCAM 57% 48% Dkk3 M2PK MIP1beta IL13 Mac2BP IGFBP2 EpCAM 57% 51% Dkk3 M2PK MIP1beta TGFbeta1 Mac2BP IGFBP2 EpCAM 57% 46% Dkk3 M2PK MIP1beta TGFbeta1 IGFBP2 TIMP1 EpCAM 57% 49% Dkk3 M2PK IL13 Mac2BP IGFBP2 TIMP1 EpCAM 57% 49% Dkk3 MIP1beta IL8 TGFbeta1 Mac2BP IGFBP2 EpCAM 57% 50% M2PK MIP1beta IL8 IL13 TGFbeta1 TIMP1 EpCAM 57% 43% M2PK IL8 IL13 TGFbeta1 IGFBP2 TIMP1 EpCAM 57% 52% Dkk3 M2PK MIP1beta Mac2BP IGFBP2 TIMP1 EpCAM 56% 47% Dkk3 IL8 IL13 Mac2BP IGFBP2 TIMP1 EpCAM 56% 48% MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 56% 54% Dkk3 M2PK MIP1beta IL8 TGFbeta1 Mac2BP EpCAM 55% 35% Dkk3 M2PK MIP1beta IL13 IGFBP2 TIMP1 EpCAM 55% 44% Dkk3 M2PK IL8 IL13 TGFbeta1 Mac2BP EpCAM 55% 35% Dkk3 IL8 IL13 TGFbeta1 Mac2BP IGFBP2 EpCAM 55% 50% Dkk3 IL8 IL13 TGFbeta1 IGFBP2 TIMP1 EpCAM 55% 54% Dkk3 M2PK MIP1beta IL8 IL13 Mac2BP EpCAM 54% 49% Dkk3 M2PK MIP1beta IL8 Mac2BP TIMP1 EpCAM 54% 39% Dkk3 M2PK IL13 TGFbeta1 IGFBP2 TIMP1 EpCAM 54% 42% Dkk3 IL8 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 54% 51% M2PK MIP1beta IL8 IL13 TGFbeta1 IGFBP2 EpCAM 54% 37% M2PK MIP1beta IL13 Mac2BP IGFBP2 TIMP1 EpCAM 54% 41% M2PK IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 54% 43% MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 EpCAM 54% 42% Dkk3 M2PK MIP1beta IL8 IL13 IGFBP2 TIMP1 53% 52% Dkk3 M2PK IL8 IL13 Mac2BP TIMP1 EpCAM 53% 42% M2PK MIP1beta IL8 TGFbeta1 IGFBP2 TIMP1 EpCAM 53% 34% M2PK MIP1beta IL13 TGFbeta1 Mac2BP IGFBP2 EpCAM 53% 45% IL8 IL13 TGFbeta1 Mac2BP IGFBP2 EpCAM 53% 51% MIP1beta IL8 IL13 Mac2BP IGFBP2 TIMP1 EpCAM 53% 39% MIP1beta IL8 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 53% 51% Table 14. Seven biomarker combinations with sensitivity <53%. BM1 BM2 BM3 BM4 BM5 BM6 BM7 Test Sensitivity at 95% Specificity Cross Validated Sensitivity at 95% Specificity M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP EpCAM 52% 42% Dkk3 M2PK MIP1beta IL13 TGFbeta1 IGFBP2 EpCAM 51% 41% Dkk3 MIP1beta IL8 IL13 TGFbeta1 TIMP1 EpCAM 51% 35% M2PK MIP1beta IL8 IL13 TGFbeta1 IGFBP2 TIMP1 51% 38% M2PK MIP1beta IL8 TGFbeta1 Mac2BP IGFBP2 TIMP1 51% 30% M2PK IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 51% 37% Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 TIMP1 50% 48% Dkk3 MIP1beta IL8 IL13 TGFbeta1 Mac2BP TIMP1 50% 41% Dkk3 MIP1beta IL8 IL13 TGFbeta1 IGFBP2 TIMP1 50% 42% M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 50% 49% M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP TIMP1 50% 35% MIP1beta IL8 IL13 TGFbeta1 IGFBP2 TIMP1 EpCAM 50% 39% Dkk3 M2PK MIP1beta IL13 TGFbeta1 IGFBP2 TIMP1 49% 44% Dkk3 MIP1beta IL8 IL13 TGFbeta1 Mac2BP EpCAM 49% 33% M2PK IL8 IL13 TGFbeta1 Mac2BP TIMP1 EpCAM 49% 43% Dkk3 M2PK MIP1beta IL13 Mac2BP TIMP1 EpCAM 48% 43% Dkk3 MIP1beta IL8 IL13 Mac2BP TIMP1 EpCAM 48% 38% Dkk3 MIP1beta IL8 TGFbeta1 Mac2BP TIMP1 EpCAM 48% 40% Dkk3 MIP1beta IL13 Mac2BP IGFBP2 TIMP1 EpCAM 48% 31% Dkk3 IL8 IL13 TGFbeta1 Mac2BP TIMP1 EpCAM 48% 38% M2PK MIP1beta IL8 IL13 Mac2BP TIMP1 EpCAM 48% 33% M2PK MIP1beta IL13 TGFbeta1 IGFBP2 TIMP1 EpCAM 48% 45% M2PK MIP1beta TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 48% 37% M2PK MIP1beta IL13 TGFbeta1 Mac2BP TIMP1 EpCAM 47% 41% IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 47% 40% Dkk3 MIP1beta IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 46% 42% M2PK MIP1beta IL8 TGFbeta1 Mac2BP TIMP1 EpCAM 46% 30% Dkk3 M2PK MIP1beta TGFbeta1 Mac2BP TIMP1 EpCAM 45% 37% Dkk3 M2PK IL13 TGFbeta1 Mac2BP TIMP1 EpCAM 45% 41% Dkk3 MIP1beta IL8 IL13 TGFbeta1 IGFBP2 EpCAM 45% 33% Dkk3 MIP1beta IL8 IL13 IGFBP2 TIMP1 EpCAM 44% 40% Dkk3 MIP1beta IL8 TGFbeta1 IGFBP2 TIMP1 EpCAM 44% 43% Dkk3 MIP1beta IL13 TGFbeta1 Mac2BP TIMP1 EpCAM 44% 43% MIP1beta IL8 IL13 TGFbeta1 Mac2BP TIMP1 EpCAM 44% 28% Dkk3 M2PK MIP1beta IL13 TGFbeta1 Mac2BP TIMP1 43% 31% Dkk3 MIP1beta IL13 TGFbeta1 IGFBP2 TIMP1 EpCAM 42% 40% MIP1beta IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 42% 31% Dkk3 M2PK MIP1beta IL13 TGFbeta1 Mac2BP EpCAM 41% 23% Dkk3 M2PK MIP1beta IL13 TGFbeta1 TIMP1 EpCAM 41% 33% Dkk3 MIP1beta IL13 TGFbeta1 Mac2BP IGFBP2 EpCAM 41% 41% Dkk3 MIP1beta TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 41% 39% Dkk3 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 41% 37% M2PK MIP1beta IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 32% 27% Table 15. Sensitivity of nine biomarker combinations in plasma and serum samples at 95% specificity. BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 Plasma Serum Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 73% 77% Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 EpCAM 73% 77% Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP TIMP1 EpCAM 54% 72% Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 IGFBP2 TIMP1 EpCAM 58% 74% Dkk3 M2PK MIP1beta IL8 IL13 Mac2BP IGFBP2 TIMP1 EpCAM 74% 70% Dkk3 M2PK MIP1beta IL8 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 71% 78% Dkk3 M2PK MIP1beta IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 57% 72% Dkk3 M2PK IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 67% 76% Dkk3 MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 54% 55% M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 58% 69% Table 16. Sensitivity of ten biomarker combinations in plasma and serum samples at 95% specificity. BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 BM1o Plasma Serum Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 70% 55% Dkk3 M2PK MIP1beta IL8 IL13 TGFbeta1 Mac2BP IGFBP2 TIMP1 EpCAM 73% 68% - It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
- All publications discussed and/or referenced herein are incorporated herein in their entirety.
- The present application claims priority from AU 2010903140, the entire contents of which are incorporated herein by reference.
- Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
-
- Anderson and Hunter (2006) Mol Cell Proteomics, 5:573-588.
- Cancer in Australia, an overview (2008) AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries), Cancer series no. 46, Cat. No: CAN 42, Canberra: AIHW.
- Etzioni et al. (2003) Nat Rev Cancer, 3:243-252.
- Hundt et al. (2007) Cancer Epidemiol Biomarkers Prev, 16:1935-1953.
- Kimmel (1987) Methods Enzymol, 152:507-511.
- Kwoh et al. (1989) Proc Natl Acad Sci USA. 86:1173-1177.
- Levin (2004) Gastroenterology, 127:1841-1844.
- Lieberman (2010) Gastroenterology, 138:2115-2126.
- Morikawa et al. (2005) Gastroenterology, 129:422-428.
- Notomi et al. (2000) Nucleic Acids Res. 28:E63.
- Tonus (2006) World J Gastroenterol, 12:7007-7011.
- Wahl and Berger (1987) Methods Enzymol, 152:399-407.
- Walker et al. (1992a) Proc Natl Acad Sci USA. 89:392-396.
- Walker et al. (1992b) Nucleic Acids Res. 20:1691-1696.
Claims (16)
- A method for diagnosing or detecting colorectal cancer in a subject, the method comprising:i) determining the presence and/or level of at least three biomarkers selected from M2PK, IGFBP2, DKK-3, EpCAM, IL-13, IL-8, MAC2BP, MIP1β, TGFβ1 and TIMP-1 in a sample from the subject,
wherein the presence and/or level of the three biomarkers is indicative of colorectal cancer. - The method of claim 1, wherein the at least three biomarkers are selected from M2PK, IGFBP2, DKK-3, EpCAM, IL-13, MIP1β, TGFβ1, IL-8, and MAC2BP.
- The method of claim 1 or 2, wherein the method comprises determining the presence and/or level of at least three biomarkers selected from M2PK, IGFBP2, DKK-3, EpCAM, IL-13 and IL-8.
- The method of any one of the preceding claims, wherein the method comprises determining the presence and/or level of three biomarkers, wherein the three biomarkers are:i) DKK-3, M2PK, and IGFBP2; orii) M2PK, IGFBP2, and EpCAM.
- The method of any one of claims 1 to 3, wherein the method comprises determining the presence and/or level of expression of at least four of the biomarkers.
- The method according to claim 5, wherein the four biomarkers are DKK-3, M2PK, MAC2BP and IGFBP2.
- The method of any one of claims 1 to 6, wherein the method comprises determining the presence and/or level of:(i) at least five of the biomarkers; or(i) at least six of the biomarkers; or(ii) at least seven of the biomarkers; or(iii) at least eight of the biomarkers; or(iv) at least nine of the biomarkers; or(v) at least ten of the biomarkers.
- The method of any one of the preceding claims, wherein the method comprises detecting the presence and/or level of least one additional biomarker selected from IGF-I, IGF-II, IGF-BP2, Amphiregulin, VEGFA, VEGFD, MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-2, ENA-78, MCP-1, MIP-1β, IFN-γ, IL-10, IL-1β, IL-4, IL-6, MAC2BP, Tumor M2 pyruvate kinase, M65, OPN, DKK-3, TGFβ-1, and VEGFpan.
- The method of any one of the preceding claims, wherein the method diagnoses or detects colorectal cancer with:i) a sensitivity of at least 50%; orii) a sensitivity of at least 66%; oriii) a sensitivity of at least 77%.
- The method of any one of the preceding claims, wherein the method diagnoses or detects Dukes Stage A colorectal cancer with:i) a sensitivity of at least 50% and a specificity of at least 95%; orii) a sensitivity of at least 60% and a specificity of at least 80%; oriii) a sensitivity of at least 50% and a specificity of at least 90%.
- The method of any one of the preceding claims, wherein the method comprises contacting the sample with at least one compound that binds a biomarker polypeptide.
- The method of claim 11, wherein the compound is detectably labelled.
- The method of any one of the preceding claims, wherein the method comprises:i) determining the presence and/or level of the biomarkers in the sample from the subject; andii) comparing the presence and/or level of the biomarkers to a control, wherein a presence and/or level in the sample that is different to the control is indicative of colorectal cancer.
- The method of any one of the preceding claims, wherein the sample is blood, plasma, serum, urine, platelets, megakaryocytes or faeces.
- An array of at least two compounds for the diagnosis or detection of colorectal cancer, wherein each of the compounds binds a different biomarker polypeptide selected from M2PK, IGFBP2, DKK-3, EpCAM, IL-13, IL-8, MAC2BP, MIP1β, TGFβ1 and TIMP-1.
- A kit for diagnosing or detecting colorectal cancer in a subject, the kit comprising two compounds that each binds a different biomarker polypeptide selected from M2PK, IGFBP2, DKK-3, EpCAM, IL-13, IL-8, MAC2BP, MIP1β, TGFβ1 and TIMP-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010903140A AU2010903140A0 (en) | 2010-07-14 | Diagnostic for colorectal cancer | |
EP11806149.8A EP2593795A4 (en) | 2010-07-14 | 2011-07-14 | Diagnostic for colorectal cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11806149.8A Division EP2593795A4 (en) | 2010-07-14 | 2011-07-14 | Diagnostic for colorectal cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2829881A2 true EP2829881A2 (en) | 2015-01-28 |
EP2829881A3 EP2829881A3 (en) | 2015-05-13 |
EP2829881B1 EP2829881B1 (en) | 2017-08-23 |
Family
ID=45468816
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11806149.8A Withdrawn EP2593795A4 (en) | 2010-07-14 | 2011-07-14 | Diagnostic for colorectal cancer |
EP14178981.8A Active EP2829881B1 (en) | 2010-07-14 | 2011-07-14 | Diagnostic for colorectal cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11806149.8A Withdrawn EP2593795A4 (en) | 2010-07-14 | 2011-07-14 | Diagnostic for colorectal cancer |
Country Status (13)
Country | Link |
---|---|
US (2) | US20130345322A1 (en) |
EP (2) | EP2593795A4 (en) |
JP (1) | JP6061344B2 (en) |
CN (2) | CN105755112B (en) |
AU (1) | AU2011279555B2 (en) |
BR (1) | BR112013000745B1 (en) |
DK (1) | DK2829881T3 (en) |
ES (1) | ES2653646T3 (en) |
IN (1) | IN2013CN01129A (en) |
NO (1) | NO2829881T3 (en) |
PT (1) | PT2829881T (en) |
RU (1) | RU2013103995A (en) |
WO (1) | WO2012006681A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2829881T3 (en) * | 2010-07-14 | 2017-12-04 | Vision Tech Bio Pty Ltd | Colorectal cancer diagnostic |
US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
JP2014510265A (en) | 2011-02-02 | 2014-04-24 | アムジェン インコーポレイテッド | Methods and compositions for inhibition of IGF-IR |
HUE042708T2 (en) | 2012-08-09 | 2019-07-29 | Inst Nat Sante Rech Med | Diagnostic of heart failure |
GB201218341D0 (en) * | 2012-10-12 | 2012-11-28 | Orign Sciences Ltd | Diagnostic method |
WO2015149030A1 (en) * | 2014-03-28 | 2015-10-01 | Applied Proteomics, Inc. | Protein biomarker profiles for detecting colorectal tumors |
EP3170005B1 (en) * | 2014-07-18 | 2019-04-10 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
CN106191215B (en) * | 2015-04-29 | 2020-03-24 | 中国科学院上海生命科学研究院 | Screening and application of protein molecular marker Dkk-3 related to muscular atrophy |
KR102561720B1 (en) * | 2015-05-12 | 2023-07-28 | 수퍼랩 파 이스트 리미티드 | Determination method of interferon having direct inhibitory effect on tumor and use thereof |
CN105219844B (en) * | 2015-06-08 | 2018-12-14 | 华夏京都医疗投资管理有限公司 | Gene marker combination, kit and the disease risks prediction model of a kind of a kind of disease of screening ten |
CN105021828B (en) * | 2015-07-20 | 2017-07-28 | 上海交通大学医学院附属新华医院 | By detecting that three phase colorectal carcinoma patients serums predict tumor patient prognosis |
CN105567846A (en) * | 2016-02-14 | 2016-05-11 | 上海交通大学医学院附属仁济医院 | Kit for detecting bacteria DNAs in faeces and application thereof in colorectal cancer diagnosis |
JP6984862B2 (en) * | 2017-03-15 | 2021-12-22 | 国立大学法人金沢大学 | Detection of colorectal cancer using blood chemokines as markers |
CN107164535A (en) * | 2017-07-07 | 2017-09-15 | 沈阳宁沪科技有限公司 | A kind of noninvasive high flux methylates diagnosis of colon cancer, research and treatment method |
CN110540588B (en) * | 2018-05-28 | 2022-08-23 | 香港中文大学 | Epitope polypeptide based on tumor stem cell marker EpCAM and application thereof |
CN108957014A (en) * | 2018-09-27 | 2018-12-07 | 郑州大学第附属医院 | Colorectal cancer blood serum designated object, expression appraisal procedure, kit and application |
CN113825440B (en) * | 2018-10-23 | 2022-10-18 | 布莱克索恩治疗公司 | System and method for screening, diagnosing and stratifying patients |
JP7442967B2 (en) | 2018-11-30 | 2024-03-05 | トヨタ紡織株式会社 | center bracket |
CN109504778B (en) * | 2019-01-11 | 2021-11-09 | 复旦大学附属中山医院 | 5hmC multi-molecular marker based on apparent modification and colorectal cancer early diagnosis model |
JP2022522803A (en) * | 2019-03-01 | 2022-04-20 | アドバンスド マーカー ディスカバリー エセ. エレ. | Diagnostic protein signature for colorectal cancer and / or its precancerous stage |
JP7300660B2 (en) * | 2019-04-03 | 2023-06-30 | 京都府公立大学法人 | Methods for detecting colorectal cancer |
JP7032764B2 (en) * | 2019-04-03 | 2022-03-09 | 京都府公立大学法人 | How to detect colorectal cancer |
EP3835789A1 (en) | 2019-12-13 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Biomarker panel for diagnosing colorectal cancer |
WO2022130597A1 (en) * | 2020-12-18 | 2022-06-23 | 国立大学法人東北大学 | Inference device, inference method, inference program, generation device, and inference system |
JP2024517664A (en) * | 2021-04-20 | 2024-04-23 | ビジョン・テク・バイオ・プロプライエタリー・リミテッド | Biomarkers for Colorectal Cancer |
CA3228665A1 (en) * | 2021-08-11 | 2023-02-16 | Trevor Lockett | Method of detecting adenoma |
WO2023128429A1 (en) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | Method for screening colorectal cancer and advanced adenoma, and application thereof |
WO2023128419A1 (en) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | Method for screening colorectal cancer and colorectal polyps or advanced adenomas and application thereof |
CN114594259B (en) * | 2022-04-22 | 2022-09-13 | 北京易科拜德科技有限公司 | Novel model for colorectal cancer prognosis prediction and diagnosis and application thereof |
PL441319A1 (en) * | 2022-05-31 | 2023-12-04 | Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu | Set of protein biomarkers and in vitro method for diagnosing colorectal cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004198419A (en) * | 2002-12-13 | 2004-07-15 | Bayer Healthcare Llc | Detection method using timp1 |
US20050014165A1 (en) * | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
EP2280285A1 (en) * | 2003-09-15 | 2011-02-02 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
BRPI0401830A (en) | 2004-05-25 | 2006-01-17 | Bentonit Uniao Nordeste Sa | Production Process of Dry Granulated Powders |
WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
WO2008073660A1 (en) | 2006-11-09 | 2008-06-19 | University Of Washington | Molecules and methods for treatment and detection of cancer |
WO2008079269A2 (en) * | 2006-12-19 | 2008-07-03 | Genego, Inc. | Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom |
CA2676227A1 (en) | 2007-02-12 | 2008-08-21 | The Johns Hopkins University | Early detection and prognosis of colon cancers |
JP5409395B2 (en) * | 2007-02-27 | 2014-02-05 | セントクローネ インターナショナル エービー | Multiplex detection of tumor cells using a panel of agents that bind to extracellular markers |
WO2008116178A2 (en) * | 2007-03-21 | 2008-09-25 | Vanderbilt University | Systems and methods for diagnosis and prognosis of colorectal cancer |
WO2008138522A1 (en) * | 2007-05-10 | 2008-11-20 | Roche Diagnostics Gmbh | Use of timp-1 as a marker for colorectal cancer |
EP2559771A3 (en) * | 2007-05-17 | 2013-06-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
CA2688558A1 (en) * | 2007-06-04 | 2009-03-26 | Diagnoplex | Biomarker combinations for colorectal cancer |
US20090017463A1 (en) * | 2007-07-10 | 2009-01-15 | Vanderbilt University | Methods for predicting prostate cancer recurrence |
US20110059464A1 (en) * | 2008-04-08 | 2011-03-10 | Muraca Patrick J | Biomarker Panel For Prediction Of Recurrent Colorectal Cancer |
US20100111969A1 (en) * | 2008-10-31 | 2010-05-06 | Apogenix Gmbh | Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors |
CA2745376A1 (en) * | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
CN102308212A (en) * | 2008-12-04 | 2012-01-04 | 加利福尼亚大学董事会 | Materials and methods for determining diagnosis and prognosis of prostate cancer |
WO2010096674A2 (en) * | 2009-02-20 | 2010-08-26 | The Regents Of The University Of California | A+ biomarker assays |
US20110177525A1 (en) * | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
DK2829881T3 (en) | 2010-07-14 | 2017-12-04 | Vision Tech Bio Pty Ltd | Colorectal cancer diagnostic |
-
2011
- 2011-07-14 DK DK14178981.8T patent/DK2829881T3/en active
- 2011-07-14 EP EP11806149.8A patent/EP2593795A4/en not_active Withdrawn
- 2011-07-14 JP JP2013518909A patent/JP6061344B2/en active Active
- 2011-07-14 RU RU2013103995/15A patent/RU2013103995A/en not_active Application Discontinuation
- 2011-07-14 AU AU2011279555A patent/AU2011279555B2/en active Active
- 2011-07-14 IN IN1129CHN2013 patent/IN2013CN01129A/en unknown
- 2011-07-14 PT PT141789818T patent/PT2829881T/en unknown
- 2011-07-14 US US13/809,785 patent/US20130345322A1/en not_active Abandoned
- 2011-07-14 WO PCT/AU2011/000895 patent/WO2012006681A1/en active Application Filing
- 2011-07-14 EP EP14178981.8A patent/EP2829881B1/en active Active
- 2011-07-14 CN CN201511009181.5A patent/CN105755112B/en active Active
- 2011-07-14 NO NO14178981A patent/NO2829881T3/no unknown
- 2011-07-14 BR BR112013000745-1A patent/BR112013000745B1/en active IP Right Grant
- 2011-07-14 CN CN201180034158.5A patent/CN103140760B/en active Active
- 2011-07-14 ES ES14178981.8T patent/ES2653646T3/en active Active
-
2017
- 2017-03-28 US US15/471,147 patent/US10877039B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
Non-Patent Citations (26)
Title |
---|
"AJCC Cancer Staging Manual", 2010, SPRINGER, pages: 143 - 164 |
"Cancer in Australia, an overview (2008) AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries", CANCER SERIES NO. 46, CAT. NO: CAN 42, CANBERRA: AIHW, 2008 |
"Essential Molecular Biology: A Practical Approach", vol. 1, 2, 1991, IRL PRESS |
ANDERSON; HUNTER, MOL CELL PROTEOMICS, vol. 5, 2006, pages 573 - 588 |
AUSUBEL ET AL.,: "Short Protocols in Molecular Biology, 3rd ed.,", 1995, WILEY |
D.M. GLOVER AND B.D. HAMES: "DNA Cloning: A Practical Approach", vol. 1-4, 1995, IRL PRESS |
ED HARLOW AND DAVID LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOUR LABORATORY |
ETZIONI ET AL., NAT REV CANCER, vol. 3, 2003, pages 243 - 252 |
F.M. AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1988, GREENE PUB. ASSOCIATES AND WILEY-INTERSCIENCE |
HUNDT ET AL., CANCER EPIDEMIOL BIOMARKERS PREV, vol. 16, 2007, pages 1935 - 1953 |
J. PERBAL: "A Practical Guide to Molecular Cloning", 1984, JOHN WILEY AND SONS |
J. SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual, 3rd edn,", 2001, COLD SPRING HARBOUR LABORATORY PRESS |
J.E. COLIGAN ET AL. (: "Current Protocols in Immunology", JOHN WILEY & SONS |
KIMMEL, METHODS ENZYMOL, vol. 152, 1987, pages 507 - 511 |
KWOH ET AL., PROC NATL ACAD SCI USA., vol. 86, 1989, pages 1173 - 1177 |
LEVIN, GASTROENTEROLOGY, vol. 127, 2004, pages 1841 - 1844 |
LIEBERMAN, GASTROENTEROLOGY, vol. 138, 2010, pages 2115 - 2126 |
MORIKAWA ET AL., GASTROENTEROLOGY, vol. 129, 2005, pages 422 - 428 |
NATURE GENETICS, vol. 21, no. 1, 1999 |
NOTOMI ET AL., NUCLEIC ACIDS RES., vol. 28, 2000, pages E63 |
R. SCOPES: "Protein Purification - Principals and Practice, 3rd edn,", 1994, SPRINGER |
SAMBROOK ET AL.: "Molecular Cloning, 3rd ed.,", 2001, COLD SPRING HARBOR LABORATORY PRESS |
TONUS, WORLD J GASTROENTEROL, vol. 12, 2006, pages 7007 - 7011 |
WAHL; BERGER, METHODS ENZYMOL, vol. 152, 1987, pages 399 - 407 |
WALKER ET AL., NUCLEIC ACIDS RES., vol. 20, 1992, pages 1691 - 1696 |
WALKER ET AL., PROC NATL ACAD SCI USA., vol. 89, 1992, pages 392 - 396 |
Also Published As
Publication number | Publication date |
---|---|
CN103140760A (en) | 2013-06-05 |
EP2593795A1 (en) | 2013-05-22 |
US20170205414A1 (en) | 2017-07-20 |
WO2012006681A1 (en) | 2012-01-19 |
IN2013CN01129A (en) | 2015-07-31 |
EP2829881A3 (en) | 2015-05-13 |
EP2593795A4 (en) | 2014-01-22 |
JP6061344B2 (en) | 2017-01-18 |
BR112013000745A2 (en) | 2016-05-24 |
CN103140760B (en) | 2016-01-27 |
JP2013533977A (en) | 2013-08-29 |
AU2011279555B2 (en) | 2016-10-20 |
CN105755112B (en) | 2019-06-07 |
EP2829881B1 (en) | 2017-08-23 |
AU2011279555A1 (en) | 2013-01-31 |
PT2829881T (en) | 2017-11-29 |
BR112013000745B1 (en) | 2021-02-02 |
US10877039B2 (en) | 2020-12-29 |
US20130345322A1 (en) | 2013-12-26 |
RU2013103995A (en) | 2014-08-20 |
CN105755112A (en) | 2016-07-13 |
DK2829881T3 (en) | 2017-12-04 |
ES2653646T3 (en) | 2018-02-08 |
NO2829881T3 (en) | 2018-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10877039B2 (en) | Diagnostic for colorectal cancer | |
US9964542B2 (en) | Bladder cancer detection composition, kit, and associated methods | |
CN105102631A (en) | Molecular diagnostic test for cancer | |
EP4063522A1 (en) | Composition for predicting response to standard preoperative chemoradiation therapy and prognosis following treatment, and method and composition for predicting patients with very unsatisfactory prognoses following standard therapy | |
US20180238890A1 (en) | Methods and materials for detection, diagnosis and management of ovarian cancer | |
CN113234830B (en) | Product for lung cancer diagnosis and application | |
CN113981098A (en) | Biomarker for liver cancer diagnosis and liver cancer prognosis prediction | |
CN115087869A (en) | Multiple biomarkers for lung cancer diagnosis and application thereof | |
EP2680003A1 (en) | Serum biomarker for diagnosing colorectal cancer | |
US20150376723A1 (en) | Prognostic biomarkers for influenza | |
CN114107504A (en) | Biomarker for detecting lung cancer and prognosis of lung cancer | |
CN113943815A (en) | ALK-based biomarker panel and application thereof | |
CN113981097A (en) | HSPA 4-based biomarker group and application thereof in liver cancer | |
CN112795658A (en) | Biomarker-based diagnosis of early colorectal cancer | |
CN114015778A (en) | Biomarker panel for predicting lung cancer | |
CN112921095A (en) | Biomarker for diagnosing early colorectal cancer and application thereof | |
CN112921094A (en) | Biomarker for assessing early colorectal cancer | |
CN112921096A (en) | Prediction of early colorectal cancer | |
CN113061657A (en) | Product and system for diagnosing early colorectal cancer | |
CN113025717A (en) | Indicators of early colorectal cancer | |
CN118251595A (en) | Method for detecting adenoma | |
CA3216160A1 (en) | Biomarkers for colorectal cancer | |
CN118048455A (en) | Colorectal cancer marker and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
17P | Request for examination filed |
Effective date: 20140729 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2593795 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101AFI20150407BHEP Ipc: C12Q 1/68 20060101ALI20150407BHEP |
|
R17P | Request for examination filed (corrected) |
Effective date: 20151112 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
17Q | First examination report despatched |
Effective date: 20160629 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170221 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2593795 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 921902 Country of ref document: AT Kind code of ref document: T Effective date: 20170915 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011041001 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2829881 Country of ref document: PT Date of ref document: 20171129 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20171122 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20171127 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: VISION TECH BIO PTY LTD |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20180104 AND 20180110 |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20170823 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2653646 Country of ref document: ES Kind code of ref document: T3 Effective date: 20180208 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: PD Owner name: VISION TECH BIO PTY LTD; AU Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION; FORMER OWNER NAME: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION Effective date: 20171211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171223 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171124 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171123 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011041001 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
26N | No opposition filed |
Effective date: 20180524 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180714 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20110714 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170823 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 921902 Country of ref document: AT Kind code of ref document: T Effective date: 20170823 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602011041001 Country of ref document: DE Owner name: VISION TECH BIO PTY LTD, AU Free format text: FORMER OWNER: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, ACTON, ACT, AU |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: VISION TECH BIO PTY LTD; AU Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION Effective date: 20230517 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230601 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20230629 Year of fee payment: 13 Ref country code: FR Payment date: 20230522 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: PC Ref document number: 921902 Country of ref document: AT Kind code of ref document: T Owner name: VISION TECH BIO PTY LTD, AU Effective date: 20230711 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230519 Year of fee payment: 13 Ref country code: NL Payment date: 20230720 Year of fee payment: 13 Ref country code: LU Payment date: 20230719 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NO Payment date: 20230720 Year of fee payment: 13 Ref country code: IT Payment date: 20230731 Year of fee payment: 13 Ref country code: FI Payment date: 20230719 Year of fee payment: 13 Ref country code: ES Payment date: 20230821 Year of fee payment: 13 Ref country code: CH Payment date: 20230801 Year of fee payment: 13 Ref country code: AT Payment date: 20230718 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20230724 Year of fee payment: 13 Ref country code: DE Payment date: 20230720 Year of fee payment: 13 Ref country code: BE Payment date: 20230719 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240423 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240501 Year of fee payment: 14 |